Paclitaxel Release System by Rivers, Jason B et al.
Worcester Polytechnic Institute 
Digital WPI 
Major Qualifying Projects (All Years) Major Qualifying Projects 
2020-05-16 
Paclitaxel Release System 
Jason B. Rivers 
Worcester Polytechnic Institute 
Michaela Faith Johnson 
Worcester Polytechnic Institute 
Summer L. Thurlow 
Worcester Polytechnic Institute 
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all 
Repository Citation 
Rivers, J. B., Johnson, M. F., & Thurlow, S. L. (2020). Paclitaxel Release System. Retrieved from 
https://digitalcommons.wpi.edu/mqp-all/7463 
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has 
been accepted for inclusion in Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. 
For more information, please contact digitalwpi@wpi.edu. 
Paclitaxel Release System 
 
A Major Qualifying Project 
Submitted to the faculty of 
WORCESTER POLYTECHNIC INSTITUTE 
 
 
 
In partial fulfillment of the requirements for the 
Degree of Bachelor of Science 
In Chemical Engineering 
 
By: 
Michaela Johnson 
Jason Rivers 
Summer Thurlow 
 
Date: 18 May 2020 
Report Submitted to: 
 
 
 
Professor Susan Roberts, Advisor 
 
 
 
Professor Jeannine Coburn, Co-Advisor 
 
 
 
This report represents the work of WPI undergraduate students submitted to the faculty as 
evidence of completion of a degree requirement. WPI routinely publishes these reports on its web 
site without editorial or peer review. For more information about the projects program at WPI, see 
http://www.wpi.edu/Academics/Projects.  
1 
Abstract 
 
Taxus plant suspension cultures can be used to produce paclitaxel (PTX), an anticancer 
compound. Currently PTX is administered systemically, which can have severe adverse side effects. 
To minimize these effects, this project investigates the use of a plant cell culture (PCC)  delivery 
system for PTX using the cells that produce PTX in bioprocesses. Using cells that are used in the 
bioprocess not only had advantages in regards to delivery, but enables the inclusion of potentially 
synergistic compounds that may enhance the therapeutic effect of PTX. Research focused on 
exploring the retention of PTX and other specialized metabolites through processing of PCC, 
optimization of drug delivery through natural and synthetic polymer hydrogels, predicted release in 
an in vitro breast cancer model, and consideration of the pharmacokinetics of the optimized system. 
When washing 10 mL of PCC prior to lyophilization, an average of 68.3% PTX, 75% 
flavonoids, and 40% phenolics were retained through wash processing. Although polyvinyl alcohol 
hydrogel microbeads were unable to maintain integrity for extended periods of time, alginate 
hydrogel microbeads consisting of 5% sodium alginate released PTX over 24 hr without degrading. 
Nile Red dye was used to mimic PTX and showed 81.1% release over 24 hr. To reduce viability of 
breast cancer cells, the desired release concentration of 8.5 x 10-4 mg/mL was confirmed through 
cytotoxic assays, which showed approximately 75% cell death. A mapping of the pharmacokinetics 
of the optimized drug delivery system for PTX from Taxus PCC demonstrates a feasible option for 
PTX administration. 
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Chapter 1: Introduction 
 
According to the World Health Organization, cancer is the leading cause of death worldwide, 
and second in the United States [1, 2]. An estimated 1.8 million new cases of cancer will be 
diagnosed in the United States in 2020, resulting in a predicted 606,520 deaths [2]. Therefore, the 
need to progress research of the disease and treatment options to decrease mortality rates remains. 
Congress recently passed an appropriations bill that provides the National Cancer Institute with $297 
million for the 2020 fiscal year to advance oncology tools, diagnostics, treatments, and prevention 
strategies [3]. Current treatment options for cancer include chemotherapy, a form of cancer therapy 
that requires the use of drugs to destroy fast-dividing cells [4]. Common chemotherapy agents, such 
as Doxorubicin, Vinorelbine, and Capecitabine, are administered at high doses, which have dose 
limiting side effects that can cause severe health issues if not monitored closely [4, 5]. Because 
systemic drug delivery systems release the therapeutic agents via the digestive or circulatory 
systems, the administered drug can affect healthy cells and organs; thus, resulting in severe adverse 
side effects [4]. Such side effects include the damage of healthy cells in bone marrow, digestive 
tract, and reproductive systems, nerve damage, kidney malfunction, and infection [6]. Chemotherapy 
agents, such as paclitaxel (PTX), are continuously being investigated to shift from systemic to local 
administration to decrease the harmful effects that are associated with current chemotherapy options. 
The U.S. Food and Drug Administration first approved PTX as a treatment for ovarian cancer 
in 1992, and has since approved it for the treatment of breast cancer, non-small cell lung cancer, and 
AIDS-related Kaposi sarcoma under the trademark of Taxol ® [7]. PTX is currently administered 
intravenously once every two to three weeks. Depending on the patient’s treatment plan, treatments 
may require 175 mg/m² over the course of 3 hr or 135 mg/m² over the course of 24 hr per treatment, 
both followed with cisplatin [8].  
PTX is naturally produced in the bark of Pacific yew trees (Taxus spp.), which is one of five 
common potential methods in which natural products can be synthesized: heterologous expression 
systems, chemical synthesis, semi-synthesis, extraction from yew trees, and plant cell cultures [9]. 
Although PTX was first discovered through isolating the compound from the bark, it has since been 
determined that this method of crude extraction is not a sustainable option [10]. Furthermore, 
alternative methods of PTX production including heterologous expression systems are limited by 
the underdeveloped biosynthetic pathway of PTX, and chemical synthesis and semi-synthesis are 
limited by the low yields and depleting sources of PTX precursors (baccatin III and 10-
deacetylbaccatin III) [9, 11]. Therefore, Taxus suspension cultures, a method of producing PTX 
through differentiating cells from yew tree needles, bark, and stems, are used as a more sustainable 
method of producing PTX for treatment [10]. 
The therapeutic performance of drugs may be further enhanced when produced in suspension 
cultures because of the synergistic interactions that may occur between the drug compound and other 
specialized metabolites, naturally produced plant compounds that often contain medicinal properties 
[12]. Although no studies have proven to increase efficacy of PTX due to synergistic interactions, 
researchers hypothesize that other specialized metabolites enhance the drug’s cytotoxic properties 
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when produced in Taxus suspension cultures [13]. The differentiated cells from plant cell suspension 
cultures (PCC), containing these compounds, can be processed and loaded into a delivery vehicle to 
control the release rate of the therapeutic agents [14]. The local administration of PTX through the 
use of delivery vehicles can target the delivery of the drug; thus, minimizing the adverse side effects 
that are associated with current cancer therapies, including the current delivery methods for PTX 
[15]. 
In a previous Major Qualifying Project (MQP), students from Worcester Polytechnic 
Institute investigated the use of PCC to create a local delivery system for PTX. For the purposes of 
the project, students sought to increase cell-associated PTX accumulation, remove DNA from the 
cells for biocompatibility, and compare the release kinetics of free PTX to calcium alginate 
encapsulated PTX [16]. This MQP expands beyond this initial research to further provide insight on 
the delivery of PTX through PCC through the following aims:   
  
Aim 1: Develop a wash process that retains PTX, flavonoid, and phenolic compounds, and prepare 
PCC material for encapsulation. 
Aim 2: Optimize delivery of PTX, flavonoid, and phenolic compounds by encapsulating PCC 
material in a biomaterial suitable for desired delivery. 
Aim 3: Establish an in vitro model to optimize drug delivery design for maximum breast cancer cell 
culture cytotoxicity, and predict release studies for PCC delivery.   
Aim 4: Understand pharmacokinetics for components of the optimized drug delivery system to 
determine feasibility and administration parameters. 
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Chapter 2: Background 
 
2.1 Drug Delivery Systems for Chemotherapy 
 
Chemotherapy drug delivery systems (DDSs) deliver anticancer drug compounds to cancer 
cells [17]. The administration of anticancer drugs generally falls into two categories: systemic and 
local [15]. Systemic DDSs, such as intravenous or oral dosage forms, release the drugs via the 
circulatory or digestive systems and affect the entire body, including healthy cells and organs [4]. 
Common anticancer drugs used in the treatment of drug cancer such as Doxorubicin, capecitabine, 
and paclitaxel (PTX), are often administered intravenously [6]. However, because these drugs are 
administered systemically, patients can experience severe adverse side effects such as internal 
bleeding, blood clots, arrhythmia, and pericardial effusion [18, 19]. To minimize the side effects 
associated with systemic administration, targeted delivery systems for anticancer drugs have been 
in development over the past decade [20]. In these systems, physicochemical or surface interactions 
attach the anticancer drugs to the surface of nanoparticles [20]. A targeting molecule, such as an 
antibody or ligand, is also attached to the surface of the drug-nanoparticle conjugate [20]. Once 
administered systemically, the targeting molecule directs the nanoparticle towards complementary 
receptors on the surface of tumor cells; thus, resulting in more local accumulation of the anticancer 
drug on the tumor [20]. For instance, PTX-loaded poly(D,L-lactide-co-glycolide) (PLGA) 
nanoparticles are covalently conjugated to antibodies target perlecan, a cell surface protein 
overexpressed in triple-negative breast cancer that promotes tumor growth [21]. In one study, 
researchers grafted triple-negative breast cancer tumors into mice, and administered six doses (20 
mg/kg equivalent dose of PTX) of the PTX-loaded PLGA nanoparticle conjugates or Isotope IgG 
nanoparticles via tail vein injection once every 96 hr, and utilized untreated mice as a control [21]. 
Isotope IgG nanoparticles contain antibodies that lack specificity in targeting [21]. In this study, 
researchers found that Isotope IgG nanoparticles increased tumor growth inhibition by 18%, whereas 
the PTX-loaded PLGA nanoparticle conjugates increased tumor growth inhibition by 44% [21]. 
Despite targeted delivery systems increasing local accumulation of systemically administered 
anticancer drugs, physiological barriers, such as tumor penetration, tumor heterogeneity, relative 
hypoxia, and endosomal escape, limit the drug efficacy in these systems [22].  
To minimize the side effects experienced with systemic administration and bypass the 
physiological barriers associated with targeted delivery systems, local DDSs, such as topical dosage 
forms, are administered to directly apply the anticancer compounds to the tumor [22, 23]. For 
instance, carmustine, an anticancer compound used to treat high grade malignant gliomas, is loaded 
into wafers and applied directly to the tumor site [14, 24]. This method of administration bypasses 
the challenges often associated with delivering chemotherapy drugs systemically across the blood-
brain barrier, such as insufficient intratumoral concentrations of the anticancer compound [14, 24]. 
Furthermore, local DDSs meet the three criteria that characterize successful DDSs for 
chemotherapy: controlled release rate, desired drug concentration, and reduction of adverse side 
effects [25]. By meeting these criteria, the anticancer drug can effectively treat the tumor while 
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minimizing lethal side effects associated with chemotherapy [22]. One study found 8.1% of patients 
receiving chemotherapy for lymphoma, myeloma, and leukaemia die within the first 30 days [26]. 
Of those deaths, 7.5% are related to chemotherapy side effects such as neutropenic sepsis, 
multiorgan failure, and chemotherapy toxicity from impaired renal failure [26]. Therefore, it is 
crucial that chemotherapy treatments shift from systemic to local administration to minimize these 
adverse side effects. 
 
2.1.1 Local Drug Delivery Systems 
 
Local DDSs deliver compounds via direct contact to the target area, as opposed to systemic 
DDSs which deliver the therapeutic agents throughout the entire body [15]. Local administration is 
often the preferred method of drug delivery because it can deliver high drug concentrations to the 
target area with minimal side effects [15]. Examples of regularly utilized local DDSs include topical 
dosage forms. For instance, sulfacetamide sodium eye drops (Bleph®-10) are a topical treatment for 
bacterial conjunctivitis [27]. Additionally, topical dosage forms are used in chemotherapy, such as 
fluorouracil cream (Tolak®) for patients with superficial basal cell carcinoma, a type of skin cancer 
[28].  
Although some local DDSs can be applied externally, other treatment plans may require a 
vehicle to deliver the drug to the target site inside the body. Drug-eluting films, gels, wafers, rods, 
and particles can be implanted into the treatment site to control the release rate of the therapeutic 
agents [14]. Furthermore, drug, polymer, and geometry-related factors of these vehicles can affect 
the release rate of therapeutic agents from the local DDSs [29]. 
Drug-Related Factors Affect Release Kinetics 
Drug-related factors such as drug solubility and molecular size can affect drug release from 
delivery vehicles [29]. A drug’s chemical structure, including its functional groups and stereo-
chemical configuration, can affect its solubility properties [29]. These properties affect a drug’s 
ability to diffuse across the chemical gradient of the medium [29]. Drugs with high solubilities are 
readily available to pass through the gradient, resulting in a faster release [29]. However, drugs with 
lower solubilities not only have slower release rates, but complete release from the delivery vehicle 
may not be feasible [29]. Additionally, diffusion is dependent on the size of the drug molecule. As 
the diameter of the molecule increases, the drug’s physical ability to pass through the matrix hinders 
diffusion [29].  
Polymer-Related Factors Affect Release Kinetics 
Once a drug’s physicochemical properties are understood, the drug is loaded into a 
biomaterial suited to promote the desired release kinetics. Polymer properties such as polymer type, 
viscosity grade, and particle size affect drug release kinetics [29]. 
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The biomaterials used to encapsulate drugs are split into two broad categories based on their 
polymer composition: natural and synthetic [14]. Natural polymers include polysaccharides 
(alginate, hyaluronic acid, dextran, and chitosan), proteins, and peptides (collagen, albumin, elastin, 
and gelatin) [14, 30, 31]. These polymers form hydrogels easily within itself via self-assembly or 
cross-linking [14, 31, 32]. Therefore, natural polymer delivery vehicles can be readily injected into 
the body and gelation can be induced by a change in temperature, pH, and/or ionic composition [14]. 
Some natural polymers require cross-linking to form hydrogels and are surgically implanted into the 
tumor site. Regardless of administration, natural polymers create minimal immune response in the 
body and are biodegradable; thus, circumventing the need for further implant removal surgeries [14, 
33]. However, to ensure successful drug delivery through natural polymer hydrogels, one must 
consider that these materials must be in high purity to be biocompatible [14, 31].  
An example of a successful local DDS that utilizes a natural polymer delivery vehicle 
includes the administration of PTX to brain glioma-bearing mice through a biodegradable 
phospholipid-based gel (PG) system [34]. For this study, researchers injected the tumors with PTX 
loaded PG or unbound PTX, and utilized saline as a control [34]. Results showed little difference 
between the control group and the unbound PTX group, with the mice dying in a similar time frame 
(15 to 18 day survival time) [34]. However, the group treated with PTX loaded PG remained alive 
until the end of the study (>40 days) [34]. In another study, chitosan thermogel solutions loaded with 
PTX (6.4% w/v) were locally administered to mice with subcutaneous EMT-6 mammary carcinoma 
tumors [14]. Researchers compared tumor growth inhibition when they administered PTX to the 
tumors via intratumoral injections or intravenous administration and utilized saline as a control [14]. 
This study showed the thermogel injections were just as effective at inhibiting tumor growth when 
compared to intravenous administration (38-40% growth inhibition over 17 days) [14]. However, 
the mice administered with PTX systemically experienced side effects such as weight loss, while the 
mice administered with PTX locally did not [14].  
Comparatively, synthetic polymers include polyesters, polyanhydrides, polyamides, 
polycarbonates, polyorthoesters, and phosphate-based polymers [14, 30, 31]. The hydrophobic 
nature of synthetic polymers allows for long-term delivery of drugs and stabilizes water-insoluble 
drugs [14]. However, these polymers often present higher risks of immune response due to acidic 
degradation products that accumulate in the body [35]. An example of a successful synthetic drug 
delivery vehicle includes the administration of PTX through Paclimer (polyphosphoester) 
microspheres [14]. In one study, researchers injected mice with two non-small cell lung cancer lines 
(A549 and H1229) and administered Paclimer microspheres loaded with 10% wt/wt PTX via 
intratumoral injection or unbound PTX via intraperitoneal injection [14]. The microspheres were 
able to successfully deliver the drug directly to the tumor site at a rate of approximately 1-2% per 
day continuously over 90 days; thus, decreasing the A549 tumor doubling times 6-fold, and the 
H1229 tumor doubling times 3-fold when compared to the results from intraperitoneal injection [14]. 
In another study, researchers used OncoGel to locally control the release of PTX in rats with 
intracranial 9L gliosarcoma [36]. OncoGel is a DDS designed to slowly release PTX from a gel, 
ReGel. ReGel is a tri-block copolymer consisting of PLGA and polyethylene glycol [36]. For this 
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study, researchers loaded the gel with 6.3 mg/mL PTX and compared efficacy to the following 
controls: ReGel only, radiation therapy only, and OncoGel with 6.3 mg/mL PTX [36]. Once injected 
with the tumor, subjects died within 17 days when treated with ReGel only, 26 days when treated 
with radiation therapy only, and 31 days when treated with OncoGel only [36]. Therefore, using the 
OncoGel to directly deliver PTX to the tumor site, showed increased survival rates when compared 
to no drug delivery and systemic radiation therapy [36].                        
In addition to the aforementioned properties of natural and synthetic polymers, polymer 
viscosity grade and particle properties should be considered when choosing a polymer as a drug 
delivery vehicle [29]. Polymers with high viscosities are able to form a mechanically stable gel layer 
that provides a greater physical barrier for diffusion, thus extending release rates [29]. For instance, 
researchers studied the release rates of flurbiprofen (FB), a nonsteroidal anti-inflammatory drug used 
in the treatment of arthritis, from dialysis bags when loaded into low (0.32–0.44 dL/g) or high (0.7–
1.1 dL/g) viscosity PLGA nanospheres, and utilized unbound FB as a control [37]. Unbound FB 
released completely from the bag within 6 hr [37]. Within this time frame, low viscosity PLGA 
nanospheres released approximately 80% FB, and high viscosity PLGA nanospheres released 
approximately 65% FB [37]. This study demonstrates that drug release rates increase as polymer 
viscosity increases [37]. Furthermore, the polymer particle size and distribution of the particles 
influences the rate that the drug penetrates through the gel layer [29]. In one study, researchers 
loaded theophylline, a bronchodilator, into polyethylene oxide tablets to analyze the effects of 
polymer particle size on drug release rate [38]. The tablets consisted of various polyethylene oxide 
particle size fractions (20–45, 45–90, 90–180 and 180–425 μm) [38]. Dissolution tests showed that 
tablets consisting of larger particle fractions released above 60% of theophylline within the first 30 
min of the study [38]. Larger polymer fractions hydrate slowly and allow water to penetrate into the 
matrix; thus, causing a burst release of the drug [38]. Comparatively, smaller polymer particle 
fractions increase the polymer-water contact surface area. This allows the gel to crosslink faster and 
prolongs drug release [38]. This study supported this claim through water uptake tests [38]. Within 
30 min, 180-450 µm polymer particles experienced 336 ± 50% increase in the weight, whereas 20–
45 μm polymer particles experienced 275 ± 49% increase in weight [38].  
Delivery Vehicle Geometries Affect Release Kinetics 
Lastly, drug release from delivery vehicles are affected by vehicle geometries. Some types 
of vehicles previously used in cancer treatment technology include drug-eluting films, gels, wafers, 
rods, and particles [14]. The rate of diffusion of drugs from these vehicles is dependent on the 
effective surface area available for diffusion [29]. Increased surface area results in an increased drug 
release rate [39]. For instance, researchers loaded lamivudine, an HIV antiviral, into hydroxypropyl 
methylcellulose tablets and altered tablet shape to analyze the effects of tablet surface area on drug 
release rate [40]. As the researchers increased tablet thickness (3.96 mm to 5.3 mm) and held surface 
area/volume constant (approximately 0.873 mm2/mm3), the surface area decreased (327 mm2 to 234 
mm2) [40]. The tablet with the larger surface area completely released the drug within 14 hr; 
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however, within the same time frame, the tablet with the smaller surface area released 90% of the 
drug [40].     
 
2.2 Plant-Derived Chemotherapy Compounds and Natural Product Drugs 
 
 Naturally produced chemotherapy compounds can be encapsulated in delivery vehicles for 
local administration. Researchers have exploited chemical substances derived from plants for their  
therapeutic benefits since the 19th century with the development of morphine [41]. Morphine, 
derived from Papaver somniferum, contains analgesic compounds [41]. With 35,000 to 70,000 plant 
species screened for medical use, various natural compounds are used in medicine today, particularly 
within oncology [42]. Examples of naturally produced antitumor compounds are vincristine, derived 
from Catharanthus roseus, monocrotaline, derived from Crotalaria sessiliflora, and PTX, derived 
from Taxus brevifolia [41, 42]. However, due to production costs, processing times, and drug 
efficacy, many manufacturers have turned to synthetic pharmaceuticals to mimic the naturally 
produced therapeutic compounds found in plants [41]. For instance, Pfizer manufacturers irinotecan 
(Camptosar®), a chemical analog for a plant alkaloid found in Camptotheca acuminata, for the 
treatment of metastatic colorectal cancer [42]. Additionally, GlaxoSmithKline manufactures 
topotecan (Hycamtin®), another chemical analog for a plant alkaloid found in Camptotheca 
acuminata, for the treatment of ovarian and small cell lung cancer [42]. Despite the advantages of 
producing synthetic chemotherapy drugs, the safety levels and drug efficacy are questionable, 
leaving over 80% of the world dependent on natural counterparts [41]. 
2.2.1 Plant Cell Suspension Cultures for Drug Production 
To produce plant-based pharmaceutical compounds, plant cell suspension cultures (PCC) are 
used as an alternative to other pharmaceutical production methods such as microbial fermentation 
and mammalian cell-based production [43]. Through this process, undifferentiated plant calli are 
suspended in liquid media and propagated in vitro under sterile and controlled environments, such 
as those in bioreactors [43]. PCC was initially designed for the production of specialized metabolites, 
such as PTX, digoxin, and ajmalicine; however, in recent years, this method has been approved as a 
viable option to produce pharmaceutical proteins [43]. For instance, Protalix manufactures 
glucocerebrosidase (Elelyso®) injections, derived from Daucus carota suspension cultures, as an 
enzyme replacement therapy for patients with Gaucher’s disease [43]. Additionally, Greenovation 
Biotech GmbH manufactures humanized glycoproteins through Physcomitrella patens suspension 
cultures [43]. Although producing pharmaceuticals through suspension culture poses several 
limitations that are not a concern for alternative bioproduction methods, such as lower scalability, 
higher capital cost, and genetic instability, suspension cultures provide an environmentally 
conscious alternative with consistent yields that require less production time and simpler purification 
steps [43]. Researchers can produce and maintain PCCs from batch-to-batch within days or weeks 
as compared to the months  or years it takes for other bioproduction methods [43].  
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Synergistic Interactions in Plant Cell Suspension Cultures 
In addition to the aforementioned benefits of producing pharmaceuticals through PCCs, 
researchers hypothesize that the naturally produced metabolites and proteins synergistically interact 
to enhance therapeutic performance [12]. For example, one study produced artemisinin, an 
antimalarial compound, through Artemisia annua (A. annua) suspension cultures to study synergistic 
interactions for enhanced therapeutic performance [44]. In addition to artemisinin, these suspension 
cultures produce a variety of flavonoids (artemetin, casticin, chrysosplenetin, chrysosplenol-D, 
cirsilineol, and eupatorin) with antimalarial benefits [44]. To study the potential synergistic 
interactions between artemisinin and flavonoids, researchers administered artemisinin orally to 
malaria-bearing mice through either powdered dried leaves of whole plant A. annua (24 mg/kg) or 
comparable doses of pure artemisinin (24 mg/kg), and utilized a mouse chow placebo as a control 
[44]. The highest concentrations of artemisinin in the bloodstreams were reached after 30 min and 
over 60 min after administration, respectfully [44]. Whole plant A. annua demonstrated greater 
parasite killing activity when compared to the pure drug counterpart [44]. Researchers suspect that 
the flavonoids contained within the whole plant inhibited the intestinal and hepatic CYP enzymes; 
thus, increasing the bioavailability of artemisinin [44]. Furthermore, the artemisinin contained in the 
whole plant A. annua leaves decreased IC50 by 20-50%, thus demonstrating the potential synergistic 
interactions between the drug and additional naturally produced flavonoids [44]. Although the 
synergistic interaction mechanism is not fully understood, it is suspected that the flavonoids enhance 
the artemisinin-heme complex, which increases the release of free radicals [44]. As a result, the 
induced oxidative stress kills the parasites [45]. 
Researchers exploit flavonoids, as well as a variety of specialized metabolites, for their 
medicinal properties [12]. Plant specialized metabolites are generally characterized by three 
classifications: terpenoids, alkaloids, and phenolics [12]. These main types of classifications, as well 
as other metabolite classifications, are described below in terms of their location and pharmaceutical 
activity (Table 2.1). 
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Table 2.1: Classification of specialized metabolites (adopted from [12, 46, 47]). 
 
Metabolite 
Classification 
Description Produced In Pharmaceutical Activity 
Polyketides and 
Fatty Acids 
Linear combinations of acetate units ● Plant oils 
● Animal 
fats 
● Antiangiogenic 
● Antidiabetic 
Terpenoids Polymeric isoprene derivatives 
synthesized from acetate via the 
mevalonic acid pathway 
● Essential 
oils 
● Antimicrobial 
● Insecticidal 
● Antiviral 
● Antifungal 
Phenolics Present in hydroxylated aromatic 
rings 
One of the largest classes of 
specialized metabolites 
● Plants ● Antioxidant 
● Anti-Inflammatory 
● Anti-Carcinogenic 
● Bactericidal 
● Antiseptic 
● Anthelmintic 
● Antiviral 
Flavonoids Water-soluble pigments ● Plants 
● Fungi 
● Anti-Allergenic 
● Anticancer 
● Antioxidant 
● Anti-Inflammatory 
● Antiviral 
Alkaloids Contains basic nitrogen atoms, 
carbone, hydrogen, and sometimes 
oxygen, sulfur, chlorine, bromine, or 
phosphorus 
● Bacteria 
● Fungi 
● Animals 
● Plants 
● Anti-Inflammatory 
● Antibacterial 
● Antidiabetic 
● Anticancer 
● Antiarrhythmic 
● Antineoplastic 
● Anticholinergic 
Saponins Compounds whose active portions 
form colloidal solutions in water and 
precipitate cholesterol 
● Plants 
 
● Antimicrobial 
● Hemolytic 
● Antitumor 
● Anti-Inflammatory 
 
Researchers can use Taxus spp. cell cultures to produce PTX [10]. Within Taxus suspension 
cultures, various specialized metabolites, such as flavonoids and phenolics, are also synthesized [13]. 
Researchers hypothesize that these compounds synergistically interact with PTX to enhance the 
drug’s cytotoxic properties [13]. Examples of specialized metabolites naturally produced in Taxus 
cultures include flavonoids, naringin and apigenin, and phenolics, curcumin and bithionol [48-51]. 
Studies have shown, naringin or apigenin, in combination with PTX, inhibits cell proliferation, and 
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induces apoptosis and cell arrest in the G1 phase [48, 49]. Similarly, when combined with PTX, 
bithionol enhances apoptosis by decreasing pro-survival factors and increasing the expression of 
pro-apoptotic factors in the treatment of ovarian cancer [50]. Additionally, when combined with 
PTX, curcumin suppresses nuclear factor kappa B, a protein complex that controls cell survival, in 
the treatment of metastatic breast cancer [51]. Current production of PTX cannot exploit the 
beneficial effects of synergistic interactions experienced in PCC. Additional downfalls of current 
PTX production methods include the adverse side effects caused by the harsh solvents used to extract 
and deliver the drug compound [10]. Therefore, the use of PCC to produce and deliver PTX will 
reduce the inefficiencies associated with current production methods that are also applicable to other 
plant-derived drugs. 
 
2.3 Paclitaxel: A Natural Anticancer Agent 
 
2.3.1 History of Paclitaxel  
 
The United States Agriculture Department started an initiative in the 1960’s to discover 
plants with anticancer agents [7]. In 1964, researchers extracted PTX, a compound that inhibits and 
prevents the development of tumors, from the bark of Pacific yew trees (Taxus brevifolia) [7]. PTX 
was originally tested through a series of assays against both leukemias and solid tumors, and it was 
discovered to be effective against the Walker tumor inhibition assay, as well as L1210 leukemia and 
1534 (P4) leukemia [52]. PTX was originally mediocre against P-388 and L-1210 leukemia in vivo, 
which discouraged research on the drug [52]. The interest in PTX testing was revived when 
researchers confirmed PTX’s antitumor activity through testing on the mouse melanoma B16 model 
[7, 52]. In this testing, PTX was administered to mice with B16 melanoma, where these mice 
decreased tumor size in a dose-dependent manner, resulting in up to 60% cure [53]. Researchers 
believe that this effectivity was due to PTX inducing bone marrow toxicity as well as induction of 
differential signal‐transduction pathways which regulate the anti‐apoptotic protein Bcl‐2 [53]. As a 
result, PTX became a chemotherapeutic candidate for clinical development [7].  
The U.S. Food and Drug Administration (FDA) first approved PTX as a treatment for ovarian 
cancer in 1992, and has since approved it for the treatment of breast cancer, non-small cell lung 
cancer, and AIDS-related Kaposi sarcoma under the trademark of Taxol® [7]. PTX is currently 
administered through intravenous therapy (IV) once every two to three weeks [8]. Depending on the 
patient’s treatment plan, treatments may require 175 mg/m² over the course of 3 hr or 135 mg/m² 
over the course of 24 hr per treatment, both followed with cisplatin [8]. PTX binds to tubulin on the 
inner surface of microtubules, biopolymers involved in the splitting of cells during mitosis, to 
enhance the stability of the microtubules thus causing mitotic arrest [54]. By targeting these 
biopolymers, PTX is able to target fast-dividing cancer cells [54].  
However, due to its systemic delivery, PTX is not selective and affects the entire body, 
particularly the fast-dividing hair and nail cells, which leads to the hair loss and weakening of nails 
often associated with chemotherapy [54]. Patients may also experience neutropenia, as well as severe 
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cardiac disturbances including sinus bradycardia, atrioventricular conduction, and bundle branch 
blocks [55]. Furthermore, PTX is dissolved in Cremophor El, a delivery vehicle used for poorly-
water soluble drugs [55]. This solvent can cause patients to experience anaphylaxis and severe 
hypersensitivity [55]. Despite these side effects, PTX continues to be one of the most effective 
chemotherapy drugs. In efforts to utilize this drug for other forms of cancers, PTX is currently the 
subject of many clinical trials. 
Although PTX is only approved by the FDA as treatment for the four aforementioned 
cancers, the drug is currently used in clinical trials for other solid-tumor cases including 
gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, as well as sarcoma, 
lymphoma, and leukemia [54]. Some clinical trials involving PTX focus on the effects of PTX in 
conjunction with other cancer therapies. For instance, in one clinical trial, patients with advanced 
peritoneal cancer are treated with Letrozole, a hormone-based type of chemotherapy, with and 
without the presence of PTX carboplatin [56]. PTX carboplatin, a chemotherapy compound typically 
used in the treatment of small-cell lung cancers, is known for its minimal, delayed side effects [56]. 
The delayed side effects are due to the delayed interaction between the PTX carboplatin and 
nucleophilic sites of DNA [57, 58]. This delay in the interaction between PTX carboplatin and DNA 
nucleophilic sites results in less side effects on the nervous system, as well as reduced nausea, as 
compared to other treatments where these are usually significant side effects [57]. In another trial, 
researchers compare two types of therapies, proton and photon radiation therapy, in the treatment of 
esophageal cancer [59].  
Additionally, researchers are exploring different forms of PTX to reduce the adverse side 
effects associated with PTX administration. For instance, researchers incorporated PTX with 
amphipathic hybrid peptides and lipids for targeted tumor treatment [60]. This study found that 
addition of biomimetic low-density lipoproteins successfully increases the biocompatibility of the 
DDS; thus reducing negative side effects that are typically associated with PTX treatment [60]. 
These lipoproteins carry hydrophobic compounds, such as PTX, by a hydrophobic core surrounded 
by more hydrophilic compounds, such as cholesterol [60]. This cholesterol layer surrounding the 
DDS is important, because it is known that to rapidly proliferate a tumor, a large amount of 
cholesterol is required, which this DDS helps to provide [60]. Similarly, researchers have 
investigated the effects of utilizing PTX albumin-stabilized nanoparticles to treat patients with 
breast, non-small cell, and pancreatic cancer [61]. Researchers believe this form of PTX has less 
negative side effects than pure PTX due to its delivery in the form of protein nanoparticles [61]. This 
nanoparticle delivery allows for solvent-free delivery of the PTX, allowing the system to bypass any 
associated side effects [62]. This nanoparticle formulation also reduces adverse side effects by 
directing the drug to the tumor site for increased local accumulation through endogenous albumin 
transport mechanisms [62]. 
Researchers use clinical trials as a means to expand and improve PTX’s function as a 
chemotherapy drug; however, research is still need to improve upon its production. For instance, 
PTX production is inefficient in keeping up with its growing demand. Eight mature yew trees are 
needed to extract 2.5-3 g of PTX, the amount required for a typical treatment [9]. Yew trees 
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propagate sparsely and must mature for approximately 100 years before the bark is ready for 
harvesting [63]. As a result of the inefficiencies in producing PTX through yew tree extraction, PTX 
costs upward of $600,000/kg [9]. Therefore, due to the current limitations in PTX production, 
researchers are exploring more efficient ways to produce PTX. 
 
2.3.2 Production of Paclitaxel 
 
PTX is naturally produced in the bark of Pacific yew trees, which is one of the five common 
potential methods in which the drug can be synthesized: heterologous expression systems, chemical 
synthesis, semi-synthesis, extraction from yew trees, and plant cell cultures [9]. Heterologous 
expression systems involve introducing recombinant DNA or RNA that encode proteins to host cells 
to carry out chemical functions they would not otherwise [64]. However, producing metabolites 
through heterologous expression presents challenges in expressing full length proteins and 
producing substantial yields [65].  
To understand other methods of PTX production, the biosynthetic pathway of PTX must be 
understood [11]. Researchers believe the biosynthetic pathway to produce PTX has putatively 
nineteen steps; however, not all enzymatic steps are understood or confirmed [11]. As a result, 
synthetic production of PTX is not a feasible production method [11]. As an alternative, semi-
synthetic production has been considered [11]. Semi-synthetic production includes the use of the 
biosynthetic precursors harvested from yew needles [11]. PTX is a diterpenoid pseudoalkaloid with 
the chemical formula C47H51NO14, and is a member of the taxane family [66]. The most notable 
structure of all taxanes, and an important precursor in the synthesis of PTX, is the taxadine three-
ring core [67]. This core is the initial structure of all taxanes that exhibit anticancer activity [67]. 
The known pathway for PTX, including its precursors, is shown in Figure 2.1. 
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Figure 2.1: Biosynthetic pathway of PTX (adapted from [9]). 
 
Baccatin III and 10-deacetylbaccatin III are important precursors in the synthesis of PTX (Figure 
2.1) [11]. However, the supply of precursors used in the semi-synthetic pathways are depleting from 
their European and Himalayan plant sources due to the high demand [10]. Due to this depletion, 
more reliable sources of these precursors or an alternative form of PTX production is needed. 
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PTX is extracted from the bark of Pacific yew trees with aggressive solvents [10]. These 
solvents include chlorinated hydrocarbons, such as chloroform, which are dangerous to humans if 
exposed through inhalation [10]. In addition to the danger presented by the severity of the solvents, 
large amounts of the solvents are required to effectively extract PTX [10]. This presents issues 
regarding the raw material cost of the solvent, and the difficulty to then remove PTX from the large 
volume of solvent [10]. Furthermore, extraction methods produce low yields of PTX [10]. Twelve 
kg of dry bark produces only 500 mg of PTX (0.004% yield) [68]. Because the extensive extraction 
process produces low drug yields, the process is inefficient in keeping up with growing demand for 
PTX. The demand for PTX has increased from 50 kg a year to 500 kg per year [68]. This demand 
could diminish the yew tree supply within 5-10 years [68]. Therefore, researchers are investigating 
more efficient methods of PTX production to preserve these trees [10].  
The crude extraction of PTX from yew tree bark is not a sustainable method in producing 
the drug; however, less invasive methods of PTX production include extracting the compound from 
the trees’ leaves [10]. Extracting PTX from leaves does not kill the trees as bark extraction would 
and produces a greater percent yield than bark extraction (0.02%) [68]. However, this method is still 
limited by the number of Pacific yew trees in a harvest year, which is severely limited by the specific 
environment the trees grow in [10, 68]. Therefore, researchers have been exploring alternative 
methods of PTX production, such as PCC, to preserve yew tree forests and provide a sustainable 
supply of PTX. 
 
2.3.3 Taxus Plant Cell Culture 
 
While PTX is currently administered as a purified compound, the use of PCC to produce and 
deliver PTX would synthesize the drug in concert with other natural compounds. These compounds 
include precursors to PTX, and other specialized metabolites that may exhibit synergistic effects in 
treatment of cancer [51]. 
 Researchers are interested in PTX precursors to supplement natural production and produce 
synthetic chemotherapy drugs. Two of the most desired precursors are baccatin III and 10-
deacetylbaccatin-III [68]. In addition to naturally creating PTX, researchers can utilize these 
precursors to synthetically produce docetaxel, another taxane chemotherapy agent that is distributed 
under the trademark Taxotere®️ [68].  
 Although PTX is a known anticancer agent produced in Taxus PCCs, other naturally 
produced metabolites, such as phenolics and flavonoids, exhibit medicinal properties [69]. Phenolics 
are naturally produced in plant cells to protect the plants from ultraviolet radiation, or aggression by 
pathogens, parasites and predators [69]. Similarly, in humans, phenolics exhibit antioxidant 
properties and can be used for bactericides and antiseptics [12]. The antioxidant activity of phenolic 
compounds is associated with the structure of the molecule: conjugated double bonds and functional 
groups bound to the ring [70]. This structure allows phenolics to inhibit the formation of reactive 
oxygen species and interrupt free radical reactions by rapidly donating hydrogen atoms to radical 
groups [69, 70].  
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Additionally, phenolics exhibit anticancer properties [69]. For instance, researchers utilized 
phenolics isolated from strawberries, including anthocyanins and kaempferol, to inhibit the growth 
of human oral, breast, colon, and prostate cancer lines in vitro [69]. Researchers have also found that 
phenolics contained within bilberry, raspberry, tea extracts are effective anticancer agents for 
cancers such as leukemia, lymphoma, prostate, breast, lung, head, and neck cancers in vitro [69]. 
Researchers have found similar results with phenolics in vivo. For instance, researchers supplied rats 
with colon cancer anthocyanin-rich diets including bilberries, chokeberries, and grapes [69]. For 
those receiving the diet, tumor size improved after 14 days in comparison to the control group who 
did not receive this diet [69]. In another study, researchers supplied cyanidin-rich diets to mice [69]. 
Mice receiving the diet showed reduced number of skin tumors when treated twice per week as 
compared to mice who were not introduced to cyanidin [69]. 
One subclass of phenolics, flavonoids, also demonstrate medicinal properties, including 
anticancer properties. Flavonoids are a specific, hydroxylated class of phenolics, naturally produced 
in fruits and vegetables, that defend the plants from microbial infections and plaques [71, 72]. 
Similarly, flavonoids exhibit multiple beneficial effects in humans, such as anti-inflammatory and 
anticancer properties. Inflammation occurs naturally after tissue damage, infection, or chemical 
irritation [71]. The inflammation process produces reactive oxygen species, as well as reactive 
nitrogen species, including tyrosine and serine-threonine protein kinases, as the body heals itself 
[71]. Flavonoids specifically target these species by binding with ATP at the catalytic sites to inhibit 
the kinases; thus, reducing inflammation [71].  
Furthermore, flavonoids have been a focal point of chemoprevention research, as 
epidemiological and clinical studies suggest that these compounds can prevent cancer through their 
interaction with various genes and enzymes [73]. For instance, researchers have shown that 
flavonoids naturally produced in apples, onions, and wine can lower the risk of prostate, lung, 
stomach, and breast cancers [71]. Researchers attribute the anticancer properties of flavonoids to 
their ability to inhibit various proteins that promote tumor growth [71]. For instance, flavonoids 
downregulate mutant p53 proteins, proteins that are unable to suppress tumor formation. In breast 
cancer cells specifically, researchers have demonstrated that flavonoids downregulate the p53 
protein to nearly undetectable levels [71]. The inhibition of the expression of this protein can lead 
to the arrest of the cancer cells [71]. Additionally, researchers have shown that flavonoids inhibit 
heat shock proteins in breast cancer, leukemia, and colon cancer cell lines [71]. These heat shock 
proteins allow cancerous cells to survive various conditions in the body [71]. The inhibition of these 
proteins may lead to easier cancer cell death [71].  
Therefore, in addition to producing PTX, PCCs have the ability to produce other metabolites 
that exhibit medicinal properties that may enhance the cytotoxic properties of the drug. By 
encapsulating the PCC material drug performance may be enhanced, costly downstream processing 
can be bypassed, PTX loss through separation processes can be prevented, and the need for the use 
of harsh solvents that are currently used in the production and delivery of PTX can be eliminated.  
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2.4 Research Plan: Taxus Cell Culture as a Drug Delivery System for Paclitaxel 
 
Currently, PTX is an FDA approved treatment for four types of cancers: breast, ovarian, non-
small cell lung, and AIDS-related Kaposi sarcoma [7]. However, current PTX production methods 
are ineffective, produce low yields of the drug, and require processing steps with harsh solvents. As 
a result, there is current research to address these challenges in producing PTX, including the use of 
PCC to manufacture the drug. Producing PTX through PCC has various benefits including the 
following: enhanced therapeutic agents through the natural synergistic interactions within the plant 
compounds, rapid processing and maintenance time compared to other culture methods, and less 
toxic delivery systems.  
In a previous Major Qualifying Project (MQP), students from Worcester Polytechnic 
Institute investigated the possibility of using PCC to create a local delivery system for PTX. For the 
purposes of the project, students sought to increase cell-associated PTX accumulation, remove DNA 
from the cells for biocompatibility, and compare the release kinetics of free PTX to calcium alginate 
encapsulated PTX [16]. This MQP expands beyond this initial research to further provide insight on 
the delivery of PTX through a targeted PCC drug delivery system through the following aims: 
 
Aim 1: Develop a wash process that retains PTX, flavonoid, and phenolic compounds, and prepare 
PCC material for encapsulation. 
Aim 2: Optimize delivery of PTX, flavonoid, and phenolic compounds by encapsulating PCC 
material in a biomaterial suitable for desired delivery. 
Aim 3: Establish an in vitro model to optimize drug delivery design for maximum breast cancer cell 
culture cytotoxicity, and predict release studies for PCC delivery.   
Aim 4: Understand pharmacokinetics for components of the optimized drug delivery system to 
determine feasibility and administration parameters. 
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Chapter 3: Retention of Paclitaxel, Flavonoids, and Phenolics 
Through Wash Processing 
 
3.1 Background 
 
3.1.1 Production of Paclitaxel 
 
Paclitaxel (PTX) is naturally produced throughout all parts of yew trees, but is most 
concentrated in the bark [10]. Extraction of PTX from the bark requires large amounts of energy. 
However, even the most productive species of yew produce small concentrations of PTX (0.004% 
wt/wt dry) making large scale manufacturing of the drug difficult [74]. Given these small 
concentrations, it takes upwards of eight 60-year-old yew trees to treat the average patient [75]. 
Alternative methods of PTX production, such as synthetic synthesis, requires a comprehensive 
understanding of PTX’s complex biosynthetic pathway, which is currently not fully understood [9]. 
With a high demand for the drug and low concentrations of PTX naturally produced, there is a need 
to uncover alternative methods for PTX production, such as Taxus plant cell cultures (PCC) [75].  
 Although the natural supply of PTX is limited through all production avenues, PCC 
technology has emerged as a viable and renewable option for commercial supply [76]. Several 
companies worldwide, such as Python Biotech and Corean Samyang Genex, have begun exploring 
PCC for PTX production because of its improved drug yield (0.02% wt/wt dry) and noninvasive 
methods [76]. Optimizing production of PTX and other taxanes via PCC can be achieved through 
manipulating culture conditions, selecting high-producing cell lines, and adding elicitors or 
precursors [76]. In fact, current supply of PTX in the United States is through PCC. 
In Taxus PCCs, exogenously adding purified PTX to existing Taxus cultures aids in carefully 
controlling the concentration of PTX in a culture [77]. However, this method requires a constant 
supply of purified PTX, which is expensive [77]. Alternatively, researchers can add elicitors, 
chemicals that enhance synthesis of specialized metabolites in plants to ensure survival persistence 
and competitiveness, to increase PTX production in Taxus PCCs [77, 78]. The addition of abiotic 
elicitors, including metal ions and inorganic compounds such as silver complexes, copper sulphate, 
and cobalt complexes, have increased PTX production in Taxus cultures by improving the 
production of specialized metabolites in PCCs [77, 78]. In one study, researchers added silver nitrate 
to Taxus PCCs to increase PTX production [79]. Elicitation with silver nitrate minimized the 
negative effects of the plant hormone ethylene, a hormone that typically inhibits plant cell growth 
and specialized metabolite production [79]. Furthermore, researchers have discovered abiotic 
chemicals, such as methyl jasmonate (MeJA), to be successful elicitation agents for PTX in Taxus 
cultures [78, 80, 81]. MeJA, a natural plant hormone, elicits a stress signal in Taxus cells, which 
causes the cells to produce a variety of specialized metabolites, including PTX [81]. Additionally, 
MeJA plays an active role in regulating defense genes in Taxus cells, which leads to the release of 
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PTX [81]. Studies have indicated that the introduction of 100 µM MeJA in Taxus cultures can 
increase the production of PTX by more than 50% [80].  
The production of complex metabolites, such as PTX, through elicited PCCs presents 
challenges, as the level and pattern of production is often unstable and unpredictable between batches 
[74]. Currently small-scale PCC produces between 1-5 mg/mL PTX [82, 83]. However, considering 
projected demands of tens to hundreds of kg of PTX are needed per year, it is imperative that PTX 
production is improved to increase consistent PTX concentrations [83]. In one study, researchers 
used a 500 L bioreactor to produce PTX in concentrations of up to 3 mg/L after 27 days in a balloon-
type bubble reactor [84]. Even though these results are promising, scaling up PTX production via 
PCC would require more research in reactor type and conditions to maintain continuous productivity 
[85]. With these challenges, improvement in PTX production through PCC is needed to enable 
higher yields in current processes. 
After PTX is produced via PCC, the drug is extracted from the PCC media and material; 
however, there is a potential to use the cell culture material containing PTX for treatment  [10, 86, 
87]. To separate and purify PTX from PCC media and material, several steps including isolation, 
crude purification, and final purification are required [86]. Isolation of PTX from PCCs commonly 
involves liquid-liquid extraction, in which solvents can be used to separate the drug from the 
encapsulating cell culture [88]. Although isolating PTX from cell culture for therapeutic applications 
is an effective way to use the drug, using the cell culture material for treatment circumvents the 
costly and time intensive processing steps involved in drug separating and purification [12]. 
Additionally, treatment involving the PCC material takes advantage of the potential synergistic 
interactions that occur between PTX and other specialized metabolites and proteins that could 
enhance the drug’s cytotoxic properties [12]. When considering treatment involving PCC material, 
PTX and those additional metabolites must be retained when preparing the material for 
administration.  
 
3.1.2 Retention and Detection of Paclitaxel 
 
Although using PCC material does not require crude purification, it does require additional 
processing to remove the cell-based material from the media. In processing PCCs to obtain PTX, 
retention of PTX through washing and processing steps is crucial, as it is necessary for media 
components and water-soluble impurity removal to isolate the PTX and other specialized metabolites 
used in drug delivery. However, through these wash steps, PTX is lost. Because of this, optimization 
of the wash steps is necessary to minimize this PTX loss to the media and maximize the PTX 
concentration in the cells. In a previous MQP, students from Worcester Polytechnic Institute washed 
cell culture samples after lyophilizing them [16]. Washing after lyophilization led to the 85% loss in 
metabolites, such as PTX, after processing [16].  
To increase PTX retention in the plant cell material throughout processing, washing before 
lyophilizing the material through high-speed centrifugation is a promising alternative [89]. Through 
centrifugation, the cell-associated metabolites and cellular material are separated from media and 
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water-soluble compounds and localized into a pellet, allowing for an easy removal of the media-rich 
supernatant [89]. Researchers can repeat the process by replenishing the conical tube with water; 
thus, effectively washing the sample [89]. To detect PTX concentrations after processing, 
researchers can use ultra high performance liquid chromatography (UPLC) to determine the 
concentrations of PTX produced in the elicited Taxus cultures and retained through processing [90]. 
 In addition to PTX, the Taxus species produces various specialized metabolites [76]. Among 
these are flavonoids and phenolics, which provide therapeutic benefits [12]. Researchers hypothesize 
that the presence of flavonoids and phenolics could create synergistic interactions with drugs, such 
as PTX, that may enhance the therapeutic properties due to previous evidence of these metabolites 
working synergistically with other antibodies [12]. For example, phenolics residing in Taxus 
cuspidata, such as hydroxycaffeic acid and protocatechuic acid, demonstrated anticancer activities 
and enhanced the cytotoxic properties of PTX by inducing cancer cell apoptosis [91]. Due to these 
interactions, the retention of flavonoids and phenolics throughout the wash process is important and 
should be maximized. To test the retention of these metabolites, flavonoid and phenolic assays may 
be performed to analyze metabolite concentrations before and after samples are processed [92]. 
 
3.2 Methods 
 
3.2.1 Plant Cell Culture Maintenance 
 
Taxus cuspidata cell lines 48.82A.11 were grown and maintained in 50 mL liquid suspension 
cultures and transferred every 14 days to new media. Media, prepped in 4 L batches, consisted of 
0.67 L nanopure water/L media, 20 g/L sucrose (Caisson Laboratories, Smithfield, UT), 3.21 g/L 
Gamborg-B5 (PhytoTechnology Laboratories, Lenexa, KS), 0.1 µM benzyl adenine (Sigma-
Aldrich, St. Louis MO), and 2.7 µM 1-naphthaleneacetic acid (Sigma-Aldrich, St. Louis, MO). 
Erlenmeyer flasks (125 mL) were filled with 40 mL of media and closed with Bellco foam caps 
before being autoclaved on the liquid cycle (121 °C) for 20 min. In a sterile environment, 10 mL of 
14-day-old cell culture were subcultured into fresh media with 2.5 mL of filter-sterilized antioxidant 
solution containing 2.5 mg/mL ascorbic acid (Fisher Scientific, Hampton, NH), 2.5 mg/mL citric 
acid (PhytoTechnology Laboratories, Lenexa, KS), and 14.6 mg/mL L-glutamine (Caisson 
Laboratories, Smithfield, UT). All cultures were incubated in a gyratory shaker (New Brunswick 
Scientific Co. Inc, Edison, NJ, Model 44) at 125 rpm, 23 °C, and in the dark. 
 
3.2.2 Eliciting Cells with Methyl Jasmonate 
 
Seven-day-old cultures were elicited with 100 µM MeJA to promote the production of PTX 
within the cells. The following reagents were added successively to create the MeJA solution: 50 µL 
MeJA (Sigma-Aldrich, St Louis, MO, 392707), 450 µL ethanol, and 500 µL nanopure water. These 
reagents were filter-sterilized through a 0.22 µM polyvinylidene difluoride (PVDF) filter and 1 mL 
syringe (PrecisionGlide®, Becton Dickinson, Franklin Lakes, NJ) into a 1.5 mL microcentrifuge 
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tube. Each flask containing approximately 50 mL of 7-day-old culture with media and antioxidants 
was elicited with 21.8 µL of MeJA solution. Each elicited flask was covered with a Bellco cap and 
aluminum foil to prevent volatilization of MeJA. 
 
3.2.3 Wash Processing 
 
This study was performed in two phases. The first phase investigated whether the initial 
volume of PCC used in wash processing affects PTX retention. This part of the study was completed 
by comparing PTX retention in 10 mL and 25 mL washed PCC samples, as described in further 
detail in Phase 1. The second phase sought to identify whether lyophilization degrades specialized 
metabolites and PTX after being washed, as further described in Phase 2.  
 
Phase 1 
 
Within six identical 50 mL conical tubes (Eppendorf, Hamburg, Germany), 25 mL of PCC 
were added to half of the tubes, and 10 mL of PCC were added to the others using an electric pipettor. 
All tubes were filled to the 40 mL line with deionized (DI) water, and weighed to be within 0.5 g of 
each other to ensure proper balance within the centrifuge. The tubes were spun in a fixed-angle rotor 
(FA-45-6-30, Eppendorf, Hamburg, Germany) centrifuge (5808F, Eppendorf, Hamburg, Germany) 
at 9,000 g and 4 °C for 30 min. 
After centrifugation was complete, 25 mL of supernatant were removed from the tubes 
initially filled with 25 mL culture, and 30 mL were removed from the tubes initially filled with 10 
mL culture with an adjustable volume pipette. The removed supernatants were transferred to 
individual flasks, and six 1 mL samples were taken from each flask. The tubes were refilled to the 
40 mL line with DI water and reweighed. The pellet was resuspended by manually shaking the tubes. 
The tubes were centrifuged again under the same conditions for a total of three wash steps.  
At the end of the third wash step, the tubes were refilled to the 10 mL and 25 mL lines 
respectfully with DI water, and the pellets were resuspended by shaking. Four 1 mL samples were 
taken from each final culture. This wash processing procedure is presented below (Figure 3.1). 
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Figure 3.1. Flow chart of the wash processing procedure for Phase 1. 
 
All 1 mL samples were placed in an evaporative centrifuge (Vacufuge plus, Eppendorf, 
Hamburg, Germany) overnight (approximately 15 hr) under aqueous conditions (1,400 rpm, suction 
capacity: 1.8 m3/hr). Dried samples were stored at -80 °C (SU80XLE, Global Cooling Inc., Athens, 
OH) until further processing for PTX concentration retention (Section 3.2.4).  
 
Phase 2 
 
 Twenty-six 1 mL samples were taken from the initial PCC. Six 50 mL conical tubes were 
filled with 10 mL of PCC with an electric pipettor. All tubes were filled to the 40 mL line with DI 
water. The tubes were spun in a fixed-angle rotor centrifuge at 9,000 g and 4 °C for 30 min. 
 After centrifugation was complete, 30 mL of supernatant were removed from each tube with 
an adjustable volume pipette. The tubes were refilled to the 40 mL line with DI water and reweighed. 
The pellet was resuspended by manually shaking the tubes. The tubes were centrifuged again under 
the same conditions for a total of three wash steps.  
At the end of the third wash step, the tubes were refilled to the 10 mL line with DI water, and 
resuspended. After resuspension, six 1 mL samples were taken from each final culture. This wash 
processing procedure is presented below (Figure 3.2). 
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Figure 3.2. Flow chart of the wash processing procedure for Phase 2 
 
Six of the 1 mL final culture samples from each tube were lyophilized (VirTis BenchTop Pro 
with Omnitronics, SP Scientific, Stone Ridge, NY) for 24 hr to compare the effects of lyophilization 
on the retention of flavonoids, phenolics, and PTX.  
All samples were placed in an evaporative centrifuge overnight under aqueous conditions 
and stored at -80 °C until further processing for PTX (Section 3.2.4), flavonoid, and phenolic 
concentration retention (Section 3.2.5).  
 
3.2.4 UPLC Preparation 
 
Sample Preparation 
 
The dried 1 mL samples were resuspended in 1 mL acidified methanol (0.01% acetic acid). 
Samples were vortexed (Scientific Mini Vortexer, VWR, Radnor, PA) and sonicated (Aquasonic 
75HT, VWR, Radnor, PA) for 20 min on ice. The samples were manually broken up with a spatula, 
vortexed, and sonicated for another 20 min. Samples were transferred into a microcentrifuge tube 
rack and placed on a shaker (New Brunswick Scientific Co. Inc, Edison NJ, Model 44) for 30 min, 
revortexed, and centrifuged (5424, Eppendorf, Hamburg Germany) for 20 min at 16,000 rpm. From 
each supernatant, 800 µL were transferred to new microcentrifuge tubes. Samples were placed in an 
evaporative centrifuge for 2.5 hr under alcohol conditions (1400 rpm, suction capacity: 1.8 m3/hr), 
and stored at -80°C until further processing.  
 
UPLC Processing 
 
To prepare the chromatography vials for UPLC processing, the samples were resuspended 
in the following order: 25 µL methanol, 35 µL acetonitrile, and 40 µL nanopure water. In between 
adding each reagent to the samples, the samples were vortexed, sonicated, and vortexed again for a 
10 sec each to dissolve the samples completely. Once the samples were dissolved, the samples were 
filtered through a 0.22 µm PVDF and 1 mL syringe into a 2 mL UPLC vial (VWR, Radnor, PA) 
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with a low-volume (0.15 mL) insert (VWR, Radnor, PA). In between filtering each sample, the 
syringe was flushed with 1 mL acidified methanol to prevent cross-contamination between samples. 
The samples were analyzed through UPLC (Waters, Milford, MA, Acquity UPLC H-Class) 
consisting of a 10 µL injection and a 6-min separation time in which molecules are separated in a 
70:30 (v:v) water-acetonitrile solvent in a C 18 2.1x50 mm, 1.7 µm column. The samples were read 
at a wavelength of 228 nm and compared to PTX standards (0 mg/L, 12.5 mg/L, 25 mg/L, 50 mg/L, 
and 100 mg/L) (Alfa aesar, Ward Hill, MA). The concentration of PTX in each sample was found 
by measuring the area under the curve. 
 
3.2.5 Phenolics and Flavonoids Assays 
 
Sample Preparation 
 
To prepare the samples for flavonoid and phenolic assays, 1 mL samples were resuspended 
in 500 µL of acidified methanol. Samples were vortexed and broken up mechanically with a spatula 
to ensure the release of the plant compounds from the pellet. To further release the plant compounds, 
the samples were spun in a microcentrifuge for 5 min at 16,000 rpm. 
 
Flavonoids Assay 
 
The following reagents were placed directly into a 96-well plate and incubated for 30 sec: 
6.25 µL resuspended sample, 18.75 µL acidified methanol, 50 µL nanopure water, and 75 µL sodium 
nitrite (Acros, NJ, 42435-5000) (6 g/L). Note that the resuspended sample was further diluted in 
acidified methanol to ¼ to ensure concentrations fell within the standard range. Once incubated, 75 
µL aluminum chloride (Sigma-Aldrich, St Louis, MO, 7784-13-6) (22 g/L AlCl3·6H2O) was added 
to each well, followed by another 2 min incubation period. Lastly, 75 µL of 0.8 M sodium hydroxide 
(Sigma-Aldrich, St Louis, MO, 1310-73-2) were added to each well. The colorimetric absorbance 
of the plate was read on a MultiskanTM GO Microplate Spectrophotometer (Accuskan GO, Fisher 
Scientific, Hampton, NH) at 490 nm. These absorbance values were compared to catechin standards 
(0.0 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.6 mg/mL, 0.8 mg/mL, and 1.0 mg/mL) (Cayman 
Chemical, Ann Arbor, MI, 70940) which were prepared and analyzed with the same protocols as the 
samples.  
 
Phenolics Assay 
 
The following reagents were placed directly into 1.5 mL microcentrifuge tubes: 5 µL 
resuspended sample, 15 µL acidified methanol, 40 µL 0.2 M Folin-Ciocalteau reagent, and 160 µL 
700 mM sodium carbonate (Fisher Scientific, Hampton, NH, S263-500). Note that the resuspended 
sample was further diluted in acidified methanol to ¼ to ensure concentrations fell within the 
standard range. The reagents incubated for 10 min. Then the samples were spun in a microcentrifuge 
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for 1 min at 16,000 rpm. From each sample, 200 µL of supernatant were transferred to a 96-well 
plate. The colorimetric absorbance of the plate was read on a MultiskanTM GO Microplate 
Spectrophotometer at 750 nm. These absorbance values were compared to gallic acid standards (0.0 
mg/mL, 0.025 mg/mL, 0.05 mg/mL, 0.075 mg/mL, 0.10 mg/mL, and 0.20 mg/mL) (Acros Organics, 
Hampton, NH) which were prepared and analyzed with the same protocols as the samples.  
 
3.3 Results and Discussion 
 
3.3.1 Media and Cell Association of Flavonoids, Phenolics, and Paclitaxel 
 
 Metabolite association to cells, rather than to media, is necessary to prevent loss of 
metabolites through wash processing; thus, producing product containing sufficient levels of 
metabolites for a drug delivery system (DDS). Therefore, metabolite concentrations in cells and 
media were analyzed prior to processing.  
Prior to washing the cell culture, 6 initial culture samples were used to determine whether 
the PTX was cell- or media-associated. To test this association, samples were spun in a 
microcentrifuge for 5 min at 16,000 rpm. The media-rich supernatant was extracted from the cell 
pellet with a low-volume adjustable volume pipette and placed into new 1.5 mL microcentrifuge 
tubes. Specialized metabolite assays and UPLC analyses were used to determine the cell and media 
association of flavonoids, phenolics, and PTX (Figure 3.3).  
 
    
Figure 3.3: Concentration of A) flavonoids, B) phenolics, and C) PTX in initial culture samples for an elicited culture 
both in total and split into media and cell components. The data show values for two biological replicates (dots) with the 
average indicated by a line.  
 
The flavonoids, phenolics, and PTX were primarily cell associated. Approximately 0.6 mg of 
flavonoids per 1 mL of cell culture, 0.5 mg of phenolics per 1 mL of cell culture, and 0.5 mg of PTX 
per 1 mL of cell culture were associated to the cells (Figure 3.3). On the contrary, only 0.03 mg of 
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flavonoids per 1 mL of cell culture, 0.03 mg of phenolics per 1 mL of cell culture, and 0.002 mg of 
PTX per 1 mL of cell culture were associated to the media (Figure 3.3). Because of the metabolic 
association to cells, and the lack of media association, the PCC could feasibly undergo the wash 
process and retain the therapeutic components.  
 
3.3.2 Comparing Paclitaxel Retention in 10 mL and 25 mL Volumes of Plant Cell Culture 
 
Once it was determined that the therapeutic agents within the PCC were cell associated, the 
cells were washed from the media. The effects of initial cell culture volume on PTX retention were 
first analyzed. To determine the effects, 10 mL and 25 mL of initial PCC underwent the same wash 
processing procedure (Figure 3.1). The initial PTX concentrations were compared to final 
concentrations through the use of UPLC analysis.  
To obtain PTX concentrations, UPLC analysis was performed on six initial PCC samples, 
one supernatant sample from each tube for all three wash steps, and one final PCC sample from each 
tube after being resuspended to the respective initial volume (Figure 3.4).  
             
 
Figure 3.4. Concentration of PTX in A) 10 mL and B) 25 mL initial culture volumes at each stage of the wash process 
for an elicited culture. Sum of processing values are the summation of PTX in wash step samples and final culture 
samples. The error bars represent standard deviation amongst three biological replicates. A two-way ANOVA statistical 
analysis compares column means to the initial culture samples: ***=p≤0.001, ****=p≤0.0001, ns=p>0.05.  
 
Although final PTX concentrations for the 10 mL and 25 mL samples were statistically different 
from the initial PTX concentrations, the 10 mL initial culture retained more PTX through the wash 
processing when compared to the PTX retention of the 25 mL initial culture (Figure 3.4). When 
washing 10 mL of PCC, an average of 68.3% of PTX was retained from the initial culture samples 
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through three wash steps to the final culture samples (Figure 3.4). However, when washing 25 mL 
of PCC, an average of 48.2% of PTX was retained from the initial culture samples through three 
wash steps to the final culture samples (Figure 3.4).   
 To further compare the final PTX concentrations from each PCC volume to the initial PTX 
concentrations, a statistical comparison of PTX concentrations was analyzed between initial culture 
samples and final culture samples of both volumes (Figure 3.5).  
  
 
Figure 3.5. Concentration of PTX in initial culture samples compared to final culture samples from 10 mL and 25 mL 
initial volume cultures for an elicited culture. The error bars represent standard deviation amongst three biological 
replicates. A two-way ANOVA statistical analysis compares each column mean to each other: *=p≤0.05, **=p≤0.01, 
ns=p>0.05.  
 
Although the final cultures were not statistically different from each other, washing 10 mL of PCC 
showed a smaller statistical difference in PTX concentrations after being processed (Figure 3.5). The 
difference in PTX retention may be due to the difference in density of the centrifuged cells. The 10 
mL samples formed denser pellets when centrifuged compared to the 25 mL. It is hypothesized that 
more PTX is lost in the supernatant in less dense pellets. Therefore, further experimentation (Phase 
2) proceeded with washing 10 mL of PCC to retain high PTX concentrations through the wash 
processing steps.   
 
3.3.3 Effects of Lyophilization on Final Flavonoid, Phenolic, and PTX Concentrations 
 
The PCC material must be lyophilized to prepare the material for encapsulation. Therefore, 
experiments were conducted to determine if lyophilization compromises the integrity of specialized 
metabolites, including flavonoids, phenolics, and PTX after the cell culture undergoes wash 
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processing. To determine these effects, 10 mL of initial PCC were washed (Figure 3.2), and final 
culture samples, both non-lyophilized and lyophilized, were compared for metabolite and PTX 
concentrations.  
 
Analyzing the Impact of Lyophilization on Flavonoid and Phenolic Retention 
 
Once washed, retention of flavonoids and phenolics with the PCC material through the wash 
processing and lyophilization was investigated. Retention of these metabolites is important because 
of the potential synergistic interactions the compounds have with PTX, which could enhance the 
therapeutic benefits of the drug. The retention of flavonoids through the wash process is shown in 
Figure 3.6. 
 
 
Figure 3.6. Concentration of flavonoids at each stage of the wash process for an elicited culture including after 
lyophilization of final culture samples. Sum of processing values are the summation of flavonoids in wash step samples 
and respective final culture samples. The error bars represent standard deviation amongst six biological replicates. A 
two-way ANOVA statistical analysis compares column means to the initial culture samples: **=p≤0.01, ***=p≤0.001, 
ns=p>0.05. 
  
From the initial culture, 75% of the flavonoids were retained through the wash process to the final 
culture (Figure 3.6). Although showing a statistical difference from the initial culture flavonoid 
concentration, these data show that washing cells prior to lyophilization can retain a majority of 
flavonoids.  
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To determine whether lyophilization affected flavonoid retention, the statistical comparison 
of flavonoid concentrations was analyzed between final culture samples of both non-lyophilized and 
lyophilized samples (Figure 3.7).   
 
Figure 3.7. Concentration of flavonoids in the non-lyophilized and lyophilized final culture samples for an elicited 
culture. The error bars represent standard deviation amongst six biological replicates. A two-way ANOVA statistical 
analysis compares each column mean to each other: ns=p>0.05.  
 
The difference between the flavonoid concentration in the final non-lyophilized culture samples and 
the final lyophilized culture samples was statistically insignificant; thus, signifying that 
lyophilization after wash processing had little effect on flavonoid retention with the PCC material 
(Figure 3.7).  
In addition to flavonoid retention, phenolic retention through the wash processing study was 
analyzed (Figure 3.8).   
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Figure 3.8. Concentration of phenolics at each stage of the wash process for an elicited culture including after 
lyophilization of final culture samples. Sum of processing values are the summation of phenolics in wash step samples 
and respective final culture samples. The error bars represent standard deviation amongst six biological replicates. A 
two-way ANOVA statistical analysis compares column means to the initial culture samples: ****=p≤0.0001.  
 
Phenolics showed a greater loss through the wash steps when compared to flavonoids (Figure 3.8). 
From the initial culture, 40% of phenolics were retained through the wash process to the final step 
(Figure 3.8). Phenolics showed less retention than the flavonoids potentially due to their volatility 
[93]. Therefore, these compounds could have evaporated throughout the wash processing or assay 
preparation procedures.  
To determine whether lyophilization affected phenolic retention, a statistical comparison of 
phenolic concentrations was analyzed between final culture samples of both non-lyophilized and 
lyophilized samples (Figure 3.9). 
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Figure 3.9. Concentration of phenolics in the non-lyophilized and lyophilized final culture samples for an elicited 
culture. The error bars represent standard deviation amongst six biological replicates. A two-way ANOVA statistical 
analysis compares each column mean to each other: ns=p>0.05. 
 
The difference between the phenolic concentration in the final non-lyophilized culture samples and 
the final lyophilized culture samples was statistically insignificant; thus, signifying that 
lyophilization after wash processing had little effect on phenolic retention (Figure 3.9). 
 
Analyzing the Impact of Lyophilization on Paclitaxel Retention  
 
To determine the effects of lyophilization on PTX retention, a statistical comparison of PTX 
concentrations was analyzed between final culture samples of both non-lyophilized and lyophilized 
samples (Figure 3.10). 
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Figure 3.10: Concentration of PTX in the non-lyophilized and lyophilized final culture samples for an elicited culture. 
The error bars represent standard deviation amongst six biological replicates. A two-way ANOVA statistical analysis 
compares each column mean to each other: ns=p>0.05. 
 
Samples from the second experiment (Phase 2), there was a much lower retention of PTX (12.8 ± 
0.05%) when compared to the results from the first experiment (Phase 1) (68.5 ± 0.05%) (Figure 
3.10). The low PTX retention could be attributed to the quality of the initial cell culture. The cells 
used in this experiment were relatively less dense than those used in prior experiments; thus, causing 
the cells to not form a completely packed pellet when centrifuged. Therefore, more PTX could have 
been lost in the removal of the supernatant due to dispersal of the pellet. Given the loosely packed 
pellet of PCC material, it was likely that some cells were still suspended in the supernatant and were 
removed during the wash process. When the supernatant was removed, these cells were likely 
removed with it, and thus PTX was removed. It is not likely that PTX would be suspended in the 
supernatant without being bonded to a cell due to the fact that PTX is hydrophobic and DI water was 
used as the supernatant. 
Despite the low retention of PTX through the wash processing, the difference between the 
PTX concentrations in the final non-lyophilized culture samples and the final lyophilized culture 
samples was statistically insignificant; thus, signifying that lyophilization after wash processing had 
little effect on PTX integrity (Figure 3.10).  
 
3.4 Conclusions 
 
 The processing studies suggest that PTX and specialized metabolites are cell associated, 
which is optimal in creating a PCC DDS. The PCC had to be washed to remove media components 
and water-soluble impurities. In processing different volumes of initial PCC, 10 mL of initial PCC 
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retained higher PTX concentrations (68.3%) when compared to 25 mL of initial PCC (48.2%). As a 
result, further studies washed 10 mL of initial PCC to determine flavonoid and phenolic retention. 
Through wash processing, approximately 75% flavonoids and 40% phenolics were retained. In 
addition to analyzing metabolite retention, the effects of lyophilization on final culture PTX and 
specialized metabolite retention were evaluated. Lyophilization of PCC prepares the material for 
encapsulation. Post-lyophilization showed statistically no difference in these retention rates. 
Therefore, washing cells prior to lyophilization is an avenue for cell washing as compared to a 
previous MQP, in which up to 85% of flavonoids and phenolics were lost after washing lyophilized 
cell culture [16]. However, it was observed that, to obtain high retention rates, the initial cell culture 
must be dense with cell matter, and if there are not enough cells in the suspension, the culture should 
be left for an extra day before splitting or eliciting to minimize the amount of metabolites lost through 
the processing.  
For further research in processing PCC material, it is recommended that the culture be 
washed prior to lyophilization. However, it is also recommended that alternative methods be 
explored to retain higher concentrations of PTX and specialized metabolites. Possible alternatives 
include centrifuging the cell culture at different speeds or at different initial volumes. Additionally, 
washing the PCC in polar protic solvents, solvents capable of hydrogen bonding through a hydrogen 
directly bonded to an electronegative atom, other than DI water, such as acetic acid, methanol, 
ethanol, or n-propanol could have an effect on retention rates [94]. The solvent must be polar protic 
due to minimize PTX loss because of the compound’s hydrophobic properties.  
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Chapter 4: Optimization of Delivery 
 
4.1 Background 
 
4.1.1 Drug Delivery Mechanisms 
 
Paclitaxel (PTX) is systemically administered through intravenous therapy once every two 
to three weeks [8]. Depending on the patient’s treatment plan, treatments may require 175 mg/m² 
over the course of 3 hr or 135 mg/m² over the course of 24 hr per treatment, both followed with 
cisplatin [8]. Because these compounds are systemically released into the circulatory system, the 
administered drug can affect healthy cells and organs; thus, resulting in severe adverse side effects, 
such as damage of healthy cells in bone marrow, digestive tract, and reproductive systems, nerve 
damage, kidney malfunction, and infection [4, 6]. Furthermore, harsh solvents, such as those 
containing ethanol or Cremophor El, a formulation vehicle used to improve solubility of various 
poorly-water soluble drugs, are needed to deliver the hydrophobic compound [95]. These solvents 
cause patients to experience further negative side effects such as anaphylactic hypersensitivity, 
labored breathing, rashes, swelling, hives, and low blood pressure [95, 96]. Therefore, researchers 
need to explore delivery systems that minimize or eliminate these adverse side effects [95, 96].  
Local administration of PTX minimizes these side effects by directing the drug absorption 
to the cancerous tissues [14]. Localized drug delivery systems (DDSs) for hydrophobic drugs, such 
as PTX, require drug encapsulation in a polymer scaffold, which may consist of natural or synthetic 
materials [14]. However, several design challenges arise with local delivery systems including the 
natural removal and sequestration of nanomaterials by the reticuloendothelial system [14]. With this 
in mind, biocompatibility and minimal immune response is of utmost importance when choosing a 
material for local DDSs.   
 
4.1.2 Natural and Synthetic Polymers in Local Drug Delivery 
 
Researchers have explored various synthetic and natural polymers to encapsulate and deliver 
PTX, and similar plant-based drugs [14]. These polymers can be used in a variety of geometries 
including gels, nanoparticles, polymeric films, rods, and wafers [14, 97]. Hydrogels, gels consisting 
of a network of hydrophilic polymers, are promising for drug encapsulation and targeted delivery, 
as it has tunable physical properties and controllable degradability [98]. 
Researchers can form hydrogels from synthetic polymers, which have been used in drug 
delivery due to their strength, customizability, and hydrophobic properties [97]. For instance, 
polyvinyl alcohol (PVA) hydrogels are one example of a synthetic polymer DDS. When reacted 
with sodium tetraborate (Borax), PVA undergoes esterification to form a hydrogel [99]. Due to 
biocompatibility, drug compatibility, water-solubility, film forming, and good mechanical and 
swelling properties, researchers have studied PVA hydrogels for oral, transdermal, and 
intramuscular administration [99]. By altering gelling properties, solubility, and adding copolymers 
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to PVA, researchers can control the drug release from PVA hydrogels, and optimize the vehicles for 
different drugs [100]. One method that has been used to manipulate these properties is freezing and 
thawing the PVA matrix numerous times to increase physical crosslinking of the polymer, which, in 
turn, increases retention in the polymer for long-term biomedical applications [99]. Although the 
degradation, drug release, and mechanical properties of synthetic materials are easy to manipulate, 
these materials pose several limitations [97]. For example, many synthetic polymers form acidic 
degradation products that may accumulate and cause inflammation at the implant site [97]. 
Moreover, synthetic polymers are more toxic, expensive, environmentally harmful, and require a 
longer development time compared to natural counterparts [97].  
Comparatively, natural polymers are also used in local drug delivery. Commonly used 
natural polymers include gums, chitosan, silk, and polypeptides including collagen, albumin, elastin, 
and gelatin [97, 101]. These materials are ideal because they are economical, readily available, non-
toxic, and capable of chemical modifications [101]. Furthermore, natural polymers are often more 
biocompatible than synthetic polymers, thus lowering the risk of immune reaction [101]. Unlike 
synthetic polymers, many natural polymers are biodegradable which eliminates the need for further 
surgical removal [14]. An example of a natural polymer that is commonly used for drug delivery is 
alginate [102]. When crosslinked in an aqueous solution of divalent cations, such as Ca2+, alginate 
forms into a hydrogel [102]. The ability to assemble alginate gels at neutral pH and mild 
temperatures makes the material a promising choice for the encapsulation and delivery of therapeutic 
drugs, such as those that exist in a cell culture [103]. Additionally, alginate hydrogels have 
demonstrated high stability in systems ranging from 0 to 100°C, which is important for preventing 
rapid degradation in a drug delivery environment [102]. Despite the advantages of utilizing natural 
polymers for drug delivery vehicles, there are several drawbacks. These materials must be in high 
purity to retain biocompatibility [14]. Additionally, there is limited opportunity for changing 
polymer compositions to alter drug release kinetics and degradation rates [14].  
A driving mechanism of drug release from local drug delivery vehicles is the drug 
concentration gradient between the implanted biomaterial and the in vivo environment [104]. Drug 
concentration will begin to equilibrate through molecular diffusion, which, depending on the 
solubility and diffusivity of a biomaterial, governs the release kinetics [104]. An in vivo drug delivery 
vehicle containing a high concentration of drug relative to its surroundings will release the drug at a 
faster rate of diffusion compared to that of a vehicle containing a lower drug concentration [104].  
To release any remaining drug from inside the delivery vehicle to the tumor site, researchers 
can chelate hydrogels to reverse the crosslinked structure and dissolve the material [97]. This process 
bypasses the need for further removal surgery [97]. For instance, in in vitro experiments, researchers 
utilize ethylenediaminetetraacetic acid (EDTA) and sodium citrate to chelate natural polymer 
hydrogels [105]. EDTA binds with metal ions and forms chelates with both transition-metal ions 
and main-group ions [105]. In vivo, natural chelation may occur through the release of divalent ions 
that crosslink the gel into the surrounding media due to exchange reactions with monovalent cations, 
such as sodium ions [106]. 
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4.1.3 Optimizing Paclitaxel Release Kinetics Using Nile Red Dye Models 
 
 To investigate release kinetics of PTX DDSs, ultra high performance liquid chromatography 
(UPLC) analysis is a common method for measuring concentrations at various time points 
throughout the release. However, UPLC analysis is a long process that requires tedious and lengthy 
preparations, limiting the number and speed of experiments [16]. Additionally, PTX is expensive, 
and difficult to measure in small concentrations through UPLC [16]. To overcome these challenges, 
alternative methods can be used to model PTX release. 
For colored compounds, UV-Vis spectroscopy is used to define the direct relationship 
between a compound’s light absorbance and concentration [107]. UV-Vis spectroscopy is a faster 
and simpler analytical technique compared to UPLC, as it only takes seconds for the instrument to 
scan samples and report results. However, this method requires the samples to be colored and absorb 
a UV or visible light wavelength to calculate changes in concentration. 
Nile Red dye (NR) is a colored compound that can be used to mimic PTX in release 
experiments. The chemical structure of NR to PTX is compared below (Figure 4.1).  
 
     
Figure 4.1: Chemical structures of A) Nile Red and B) paclitaxel (adopted from [Sigma-Aldrich, 2020] and [Howat, 
2014]). 
 
NR is similar to PTX in solubility, as both chemicals are poorly soluble in water (<0.1 
mg/mL) but easily dissolve in polar aprotic solvents such as dimethylsulfoxide (DMSO) (>50 
mg/mL) [7, 108]. When dissolved, NR has a visible red color, absorbing the peak value of visible 
light around 560 nm [108]. Therefore, the following experiments utilized NR and UV-Vis 
spectroscopy to model PTX release from both natural and synthetic polymers to optimize the PTX 
delivery vehicle. 
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4.2 Methods 
 
4.2.1 Nile Red Dye Encapsulated in Polyvinyl Alcohol Hydrogel Release Profile 
 
The integrity of the PVA was analyzed over an extended period of time to determine if the 
material would be a viable option for PTX delivery. A 1 mg/mL stock solution of NR (Sigma-
Aldrich, St. Louis, MO) in DMSO (Fisher Scientific, Fair Lawn, NJ) was combined with 20% (w/v) 
PVA (363170 Sigma-Aldrich, St. Louis, MO) to produce beads with a 2.0 mm diameter in a 0.1 
mg/mL concentration. The PVA solution loaded with NR was formed into a droplet using a 22-
gauge needle (PrecisionGlide®, Becton Dickinson, Franklin Lakes, NJ) and a 1 mL syringe 
(PrecisionGlide®, Becton Dickinson). While the droplet was still on the tip of the needle, it was 
lowered and placed into a 24-well plate containing 1 mL of sodium tetraborate for 30 sec to crosslink. 
After 30 sec, the microbead was sheared off of the needle with a spatula into a well containing 1 mL 
of 4% (w:v) bovine serum albumin-phosphate buffered saline (BSA-PBS) (Sigma-Aldrich, St. 
Louis, MO) solution with a spatula. Duplicate sets of three beads and nine beads were created. The 
beads were placed on a shaker at room temperature (MaxQ 4000, Thermo Fisher Scientific, 
Waltham, MA) and observed over 30 min. 
 
4.2.2 Nile Red Dye Encapsulated in Alginate Hydrogel Release Profile 
 
Determining Alginate Concentration for Hydrogel Microbeads 
 
To model and predict the release profile of PTX from alginate hydrogel microbeads, a series 
of experiments were performed with NR. The first experiment determined the threshold 
concentration of low viscosity sodium alginate to maintain consistent bead integrity over 24 hours. 
A 1 mg/mL stock solution of NR suspended in DMSO was combined with four different 
concentrations (1.5%, 2%, 3%, and 5% (w/v)) of low viscosity sodium alginate (Alfa Aesar, 
Haverhill, MA) to produce microbeads of a NR concentration of 0.1 mg/mL. The sodium alginate 
solution loaded with NR was slowly added dropwise with a 22-gauge needle and a 1 mL syringe 
into a 24-well plate containing 1 mL of 100 mM calcium chloride (C1016, Sigma-Aldrich, St. Louis, 
MO), creating beads with a diameter of 1.8-2.0 mm. Beads were measured using an in-picture ruler 
scale and size estimations were made with ImageJ. Three sets of three microbeads and three sets of 
nine microbeads were added to the calcium chloride for each alginate concentration. The microbeads 
in calcium chloride were placed on a shaker for 30 min to crosslink. The calcium chloride solution 
was pipetted from each well and replaced with 1 mL of 4% (w/v) BSA-PBS solution, a protein-
buffer solution that mimics physiological fluids. The microbeads were incubated at 37 °C and 
observed over 24 hr. A schematic of how the microbeads were prepared is pictured below (Figure 
4.2).  
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Figure 4.2: Alginate hydrogel microbeads loaded with Nile Red dye preparation schematic. Solution is dropped into 
calcium chloride to crosslink, and calcium chloride is then replaced with BSA-PBS solution for the release 
experiment. 
 
Analyzing the Release Profile of Nile Red from Alginate Microbeads 
 
 To gain an understanding of the release profile of NR from alginate hydrogel microbeads, 1 
mg/mL NR was combined with 3% and 5% (w/v) low viscosity sodium alginate to produce 
microbeads with 0.1 mg/mL NR. Preparation of the microbeads was consistent with protocols from 
the aforementioned experiment. From each release media, 200 µL samples were taken every 30 min, 
and centrifuged in a microcentrifuge (5424, Eppendorf, Hamburg Germany) for 5 min at 16,000 
rpm. From each supernatant, 100 µL was pipetted into a 96-well plate and the colorimetric 
absorbance of the plate was read on a MultiskanTM GO Microplate Spectrophotometer (Accuskan 
GO, Fisher Scientific) at 552 nm. After the first 90 min, samples were taken every hour for 12 hr, 
and then again at 23 hr. Once processed, the sample was resuspended into its original well.  
 
Determining Final Nile Red Concentration in Microbeads After Release 
 
To determine the percentage of NR released from the alginate hydrogel microbeads after 23 
hr, the microbeads were chelated with EDTA disodium salt to determine the concentration of NR 
remaining in the microbeads. The BSA-PBS solution was removed from each well with a pipette, 
and the microbeads were washed with DI water 3 times. A 0.1 M stock solution of EDTA disodium 
salt (Fisher Scientific) was combined with BSA to create a 4% (w/v) BSA-EDTA solution. To each 
of the wells, 1 mL of the BSA-EDTA solution was added, and the microbeads were placed on a 
shaker for 1 hr. Once fully dissolved, 200 µL samples were taken from each well, and centrifuged 
in a microcentrifuge for 5 min at 16,000 rpm. From each supernatant, 100 µL was pipetted into a 
96-well plate and the colorimetric absorbance of the plate was read at 552 nm. 
 
 
 
45 
4.2.3 Paclitaxel Encapsulated in Alginate Hydrogel Release Profile 
 
Determining Paclitaxel Concentration for Desired Release 
 
To gain an understanding of the release profile of PTX from alginate hydrogel microbeads, 
the loading concentration of PTX had to be determined. A 1 mg/mL stock solution of PTX suspended 
in methanol was combined with 5% (w/v) low viscosity sodium alginate to produce microbeads with 
0.1, 0.05, 0.01, 0.005, 0.001 mg/mL concentrations. The sodium alginate solution loaded with PTX 
was added dropwise with a 22-gauge needle and a 1 mL syringe into a 24-well plate containing 2 
mL of 100 mM calcium chloride. The beads for this study were approximately 3.0 to 3.1 mm in 
diameter. Beads were measured using an in-picture ruler scale and size estimations were made with 
ImageJ. Triplicate sets of nine microbeads were added to the 100 mM calcium chloride solution for 
each PTX concentration. One 24-well plate was designated for the release concentrations sampled 
after 12 hr, and the other plate was designated for the release concentrations sampled after 24 hr. 
The beads were placed on a shaker for 30 min to crosslink. Once crosslinked, the calcium chloride 
was removed, and replaced with 1 mL of 4% BSA-PBS solution and incubated at 37 °C. After 12 
hr, the BSA-PBS solution was removed from each well of one 24-well plate and placed into 
microcentrifuge tubes. This process was repeated after 24 hr for the second plate. The samples were 
placed in an evaporative centrifuge overnight and stored at -80 °C until further processing for PTX 
concentrations with UPLC as detailed in Chapter 3.2.4. 
 
4.3 Results and Discussion 
 
4.3.1 Nile Red Dye Encapsulated in Polyvinyl Alcohol Hydrogel Release Profile 
 
 The integrity of the NR loaded PVA hydrogel microbeads in BSA-PBS solution were 
observed over 30 min (Figure 4.3). 
 
        
Figure 4.3: Visualization of PVA microbeads releasing NR into BSA-PBS solution at A) 5 min B) 20 min and C) 30 
min. Nine beads/well are shown in the left columns and three beads/well in the right columns. 
 
46 
Within 30 min of submerging the PVA hydrogel microbeads into the BSA-PBS solution, the 
microbeads degraded and dissolved completely; thus, releasing the total concentration of NR into 
the system (Figure 4.3). The quick degradation of the hydrogels may have been due to the lack of 
crosslinks within the matrix. Oftentimes, successful PVA hydrogel delivery vehicles have undergone 
physical modifications such as the freeze-thaw method to induce greater amounts of crosslinks 
within the matrix or have been combined with other polymers to ensure hydrogel stability [99]. 
Therefore, pure PVA was not a viable option for encapsulating PTX because there was minimal 
control of the drug’s release rate from the polymer, and no further studies were conducted with this 
material.  
 
4.3.2 Nile Red Dye Encapsulated in Calcium Alginate Hydrogel Release Profile 
 
Determining Alginate Concentration 
 
The integrity of the NR loaded calcium alginate hydrogel microbeads in BSA-PBS solution 
was observed over 24 hr (Figure 4.4).  
 
      
Figure 4.4: Visualization of alginate microbeads releasing NR into BSA-PBS solution at A) 0 hr B) 8.5 hr and C) 24 hr. 
From rows top to bottom, the low viscosity sodium alginate concentrations are: 1.5%, 2%, 3%, and 5%. Triplicates of 
three beads and nine beads were studied for each sodium alginate concentration.  
 
Within 8.5 hr of submerging the calcium alginate hydrogel microbeads into the BSA-PBS solution, 
the hydrogels consisting of 1.5% or 2% sodium alginate began to degrade (Figure 4.4). For these 
47 
concentrations, the wells containing three microbeads had either nearly or completely dissolved, 
whereas the nine microbead counterparts maintained their integrity. However, the integrity of the 
microbeads consisting of 3% or 5% sodium alginate were visually unaffected at this time.  
After 24 hr of release, all microbeads consisting of 1.5% or 2% sodium alginate had 
completely dissolved (Figure 4.4). The wells containing three microbeads of 3% or 5% sodium 
alginate began to degrade, and the nine microbead counterparts were visually unaffected. The 
integrity of hydrogels created from higher concentrations of low viscosity sodium alginate were not 
compromised over longer periods of time; thus, allowing for more control of a drug’s release. 
Moving forward, experiments performed to understand the release kinetics of NR and PTX utilized 
3% and 5% low viscosity sodium alginate.  
 
Nile Red Release Profile 
 
 The release profiles of NR from calcium alginate hydrogel microbeads consisting of 3% and 
5% sodium alginate were compared (Figure 4.5).  
 
A) B)  
Figure 4.5: Accumulated mass of NR (mg) released over 23 hr by hydrogel beads consisting of A) 3% and B) 5% low 
viscosity sodium alginate suspended in a 4% BSA-PBS solution. The initial mass of NR in three beads is 0.0034 ± 
0.0003 mg, and 0.0068 ± 0.002 mg in nine beads. Error bars represent average ± min/max of three samples. 
 
Release media containing three microbeads, for both 3% and 5% sodium alginate, reached nearly 
complete release of the NR after 12 hr (Figure 4.5). However, release media containing nine 
microbeads, for both 3% and 5% sodium alginate continued to slowly release the NR over 23 hr 
(Figure 4.5). For release media containing nine microbeads with 3% sodium alginate nearly reached 
complete release of NR after 23 hr. The data suggests that for release media containing nine 
microbeads with 5% sodium alginate, the beads would continue to slowly release the drug over 23 
hr until the concentration of NR in the beads and the release media were in equilibrium.  
 Once the alginate microbeads were chelated with EDTA, the mass percent release of NR 
over 23 hr could be determined (Figure 4.6).  
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A) B)  
Figure 4.6: Mass percent of NR released over 23 hr by hydrogel beads consisting of A) 3% and B) 5% low viscosity 
sodium alginate suspended in a 4% BSA-PBS solution. Error bars represent average ± min/max of three samples. 
 
Analyzing the mass percent release of NR from alginate hydrogels further supported that wells 
containing smaller initial volumes of NR resulted in a faster release of NR into the BSA-PBS 
solution when compared to wells containing higher initial volumes of NR (Figure 4.6). After 12 hr, 
three microbeads containing 3% sodium alginate released an average of 81.1% of the initial volume 
of NR, and nine microbeads with the same concentration released an average of 69.3% of the initial 
volume of NR. After 23 hr, the three microbeads released an average of 83.6% of the initial volume 
of NR, and the nine microbeads released an average of 90.7% of the initial volume of NR. After 12 
hr, three microbeads containing 5% sodium alginate released an average of 88.2% of the initial 
volume of NR, and nine microbeads with the same concentration released an average of 54.5% of 
the initial volume of NR. After 23 hr, the three microbeads released an average of 94.7% of the 
initial volume of NR, and the nine microbeads released an average of 81.1% of the initial volume of 
NR. 
 The release rate for microbeads containing 3% sodium alginate were comparable regardless 
of the initial volume of NR in the system, whereas after 7 hr the release rates between three and nine 
microbeads began to differentiate for microbeads containing 5% sodium alginate. As alginate 
concentration increased, the solid volume fraction and density of crosslinks increased, thus resulting 
in greater stiffness of the gel [109]. Therefore, regardless of the initial volume of NR in the systems 
containing beads consisting of 3% sodium alginate, the dye did not have to overcome a greater 
physical barrier compared to the beads created from 5% sodium alginate. With a lower crosslinking 
density, the NR was able to release from the hydrogels to near completion. However, for the beads 
containing 5% sodium alginate, the dye had to overcome a greater physical barrier to reach higher 
mass release percentages. Moving forward, experiments to understand PTX release from calcium 
alginate hydrogels were conducted with nine beads containing 5% sodium alginate to have the most 
control over the drug’s release rate.  
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4.3.3 Paclitaxel Encapsulated in Alginate Hydrogel Release Profile 
 
Determining Paclitaxel Concentration Required for Desired Release 
 
The release of PTX from calcium alginate hydrogel microbeads over 12 and 24 hr for initial 
loading concentrations of 0.1, 0.05, 0.01, 0.005, and 0.001 mg/mL were compared (Figure 4.7). 
 
Figure 4.7: Mass of PTX (mg) released over 12 and 24 hr from alginate hydrogel beads loaded with the following initial 
concentrations (mg/mL) of PTX A) 0.1, B) 0.05, C) 0.01, D) 0.005, and E) 0.001. A horizontal line represents the mean 
of three samples. 
 
From literature, the desired drug release concentration from the hydrogel beads after 24 hr is 8.5 x 
10-4 mg/mL [7]. The data above was interpolated and it was determined that 0.025 mg/mL PTX is 
required to be loaded into the beads to achieve the desired release concentration after 24 hr (Figure 
4.7). To achieve this initial bead and desired release concentrations, 0.0104 mg of 0.059 mg/L 
(Chapter 3.3) lyophilized PCC material must be added to 10 µL of sodium alginate. Theoretically, 
the release of PTX from the PCC material encapsulated in alginate hydrogels would behave similar 
to the release kinetics of the pure PTX studies.  
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In some cases, the mass of PTX released decreased between sample times (Figure 4.7). 
Incubating the beads at 37°C could have caused the PTX to degrade. Literature describes one study 
that showed PTX undergoes two types of degradation, hydrolysis and epimerization, when released 
into PBS media at 37°C over 6 hr [110]. Therefore, further experimentation to determine PTX 
integrity over 24 hr at 37°C is needed to confirm the use of a hydrogel DDS to deliver PTX within 
these environmental conditions for breast cancer cell cytotoxicity. 
 
4.4 Conclusions 
 
 Through preliminary testing, it was established that PVA is not a suitable material for the 
DDS because the crosslinked PVA beads disintegrated within 30 min. This short time frame is not 
feasible for PTX delivery, as typical treatments are administered over the course of 3 to 24 hr [111]. 
PVA is most frequently used in conjunction with other materials, such as chitosan, or as a thin 
hydrogel, rather than in the form of microbeads [112].  
Alginate in the form of hydrogel microbeads was established as a feasible option for PTX 
delivery. When testing microbeads consisting of 5% low viscosity alginate crosslinked in 100 mM 
calcium chloride, the integrity of the microbeads remained over 23 hr, indicating that the release rate 
of the drug can be better controlled. When administering PTX, increased control is ideal because 
PTX treatments are customized to each specific patient depending on their height, weight, and age. 
Therefore, 5% alginate was determined to be the ideal concentration of sodium alginate to act as an 
encapsulation polymer for the delivery of PTX through PCC material. 
 When encapsulated in 5% alginate, there was a difference in release rates in the three and 
nine microbead studies. The studies involving the three microbeads released an average of 94.7% of 
the initial NR concentration, whereas the studies with nine microbeads released an average of 81.1% 
of the initial NR concentration. A high concentration of NR in the microbeads and a low 
concentration of NR in the surrounding environment will result in large diffusion of the dye from 
the microbeads into the lowly concentrated BSA-PBS solution. In the study with the three 
microbeads, this concentration gradient drives a higher percentage of NR to release into the BSA-
PBS solution. In the nine microbead study, there is more total NR, and after the initial burst of 
diffusion, the concentration gradient of NR between the microbeads and the BSA-PBS solution is 
no longer that large, which limits, slows, and controls further diffusion. Therefore, moving forward, 
nine beads were used in experiments due to its slower release rate and increased control of the 
compound release.  
 From the PTX release studies, the ideal starting microbead concentration of PTX was 
determined to be 0.025 mg/mL through interpolating the 24-hr mass release data. Results from the 
studies were inconsistent, as the total mass release of PTX decreased from 12 to 24 hr in the 
microbeads loaded with 0.05 and 0.01 mg/mL PTX. The decrease could be due to degradation of the 
PTX, as the tests occurred at 37°C, and the drug loses stability at temperatures higher than room 
temperature. Additionally, NR may not have accurately modelled PTX release. While the solubilities 
of these chemicals are similar, the sizes of these molecular compounds are different, with PTX 
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having a molecular weight of 853.9 g/mol and NR having a molecular weight of 318.4 g/mol. A size 
difference could impact diffusion properties, as molecule size is a determinant for molecular 
diffusion rate.  
 From the experiments and research described in the above chapter, it was concluded that 
alginate hydrogels are a promising polymer for administering PTX locally. The microbeads 
containing 5% sodium alginate delivered a sustained concentration of the drug for 24 hr. Therefore, 
future research should explore the potential alginate hydrogels have for drug delivery. However, 
researchers should identify different colored compounds to mimic PTX for release studies to 
decrease raw material cost and analyzing time. Conducting UV-Vis spectroscopy to model drug 
release is an efficient and convenient method for carrying out otherwise lengthy preliminary drug 
release studies. Other compounds, with similar solubility properties and molecular weight, such as 
water insoluble vat dyes, should be explored. Vat Yellow 33 is an example of a potential modeling 
compound, as its size and solubility properties are very similar to those of PTX [Vat Yellow 33, 
2017]. 
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Chapter 5: Establishing an In Vitro Breast Cancer Model to 
Optimize Drug Delivery Design 
5.1 Background 
Currently, the U.S. Food and Drug Administration has approved paclitaxel (PTX) for the 
treatment of four different cancers: AIDS-related Kaposi sarcoma, breast cancer, non-small cell lung 
cancer, and ovarian cancer [7]. Of these cancers, breast cancer is the most prevalent, as it was the 
second most common cancer worldwide with over 2 million new cases reported in 2018 [113].  
Breast cancer patients treated with PTX on a weekly basis have an 89.7% chance of survival 
5 years after diagnosis, whereas chemotherapy treatments that require administration on a bi-weekly 
or monthly basis have an 86.5% chance of survival [114]. Weekly administration of PTX requires 
half the standard dose; thus, decreasing the severity of chemotherapy side effects that patients 
experience [114]. Given the pervasiveness and severity of the disease, it is of utmost importance to 
develop effective treatment plans. Therefore, optimal drug treatment plans vary for each patient, 
depending on the severity of their cancer, as well as how their body reacts to treatment. Regardless, 
optimizing DDSs results in less severe side effects in patients, as well as improved effectiveness in 
killing cancer cells. 
To test the efficacy of drugs on cancer cells, researchers can utilize mammalian cancer cell 
cultures [39]. Human cancer-derived cell lines are the most widely used models to study the biology 
of cancer and to test hypotheses to improve the efficacy of cancer treatment [39]. Particularly, 
mammalian cell cultures and cancer cell lines have been instrumental in testing drug delivery 
systems [115]. For example, researchers used HepG2 liver cancer cells in the development of a 
targeted drug delivery system for PTX [116]. These cells were treated with a range of concentrations 
within hydroxypropyl-β-cyclodextrin nanoparticles and as free PTX [116]. By testing the PTX 
delivery system on this cell culture, researchers determined that biotin and arginine modified 
hydroxypropyl-β-cyclodextrin nanoparticles are a successful delivery system for PTX [116]. 
Furthermore, this system was successful in delaying tumor growth and reducing tumor size [116]. 
Therefore, this chapter utilizes a cancer cell line to effectively model the effects of drug release, and 
drug efficacy against in vitro breast cancer cells.  
5.2 Methods 
5.2.1 Mammalian Cells 
 MDA-MB-231 breast cancer cells were maintained in a Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 2 mM l-glutamine (Fisher Scientific, Hampton, NH). The cells were subcultured 
2 to 3 times per week. The media was aspirated from the cells, and 5 ml DPBS (-) (Cat # 21-031-
CV, Corning) was added to rinse cells. The DPBS (-) was then aspirated, and 3ml 0.25% Trypsin 
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(Cat # 25-053-Cl, Corning) was added. The cells were incubated for 3 min at 37°C to detach the 
cells from the walls of the container. Then, 2 mL of the aforementioned media was added, and the 
cell suspension was transferred to a 15 mL conical tube. Next, 6 µl of cell suspension was removed 
and injected into a hemocytometer for cell counting. The cells were centrifuged at 200G for 5 min, 
and the media was aspirated carefully to not disturb the cell pellet. The cells were suspended in the 
amount of media that would result in a cell density of 1 x 106 cells/mL. The cells were re-plated on 
a sterile plate to achieve desired density, and media is added to obtain a total volume to 10 ml/plate.  
5.2.2 Resazurin Assay 
 A resazurin assay was used to test the cytotoxicity of PTX at varying concentrations. This 
assay measured the metabolic activity in cells, which, in turn, determined the viability of cells after 
treatment. Live cells have the ability to reduce resazurin, which is not fluorescent, to resorufin, which 
is fluorescent, through mitochondrial reductase [117]. The fluorescence of the sample is proportional 
to the amount of viable cells [117]. In this assay, 5,000 MDA-MB-231 breast cancer cells per well 
were seeded into a 96-well plate, 24 hr prior to treatment. To treat the cells, a 1 M stock solution of 
PTX was diluted through a serial dilution to create 12 PTX concentrations ranging from 0.005 nM 
to 1000 nM (100 µL each). The media covering the cells was aspirated, and 100 µL of PTX 
containing media was added to the wells. Each PTX concentration was tested in 4 replicates. Six 
control wells were not treated with PTX. The cells were left in an incubator at 37° C for 72 hr. 
 The cells were then imaged with phase contrast microscopy under 10x magnification (Nikon 
Eclipse TS100, Tokyo, Japan) to visualize cell shape and quantify. In media, 140 µL of sterile 
resazurin stock (1.5 mg/mL) was diluted 10-fold. The PTX and media solution was aspirated, and 
100 µL of the working resazurin solution was added to each well. The cells were left to incubate in 
the resazurin solution for 3 hr at 37° C. After this incubation period, the 100 µL was transferred to 
a black 96-well plate, and read with a fluorescence plate reader (Victor 3 – PerkinElmer 1420 
Multilabel Counter). 
5.3 Results and Discussion 
The resazurin assay performed on the breast cancer cells determined the viability of breast 
cancer cells at varying PTX concentrations (Figure 5.1).  
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Figure 5.1: Results of resazurin assay depicting the viability of cells exposed varying concentrations of PTX ranging 
from 0.005 nM to 1000 nM. 
 
Cell viability began to decrease when exposed to 0.45 nM PTX (Figure 5.1). The viability of the 
cells began to plateau to approximately 25% viability when exposed to 37 nM PTX (Figure 5.1). 
The viability of these cells may have plateaued at 25% because of natural resistance to the drug, or 
acquired resistance in response to previous treatments. This result is comparable to similar studies 
where cytotoxicity never reached 100%, and viability levels plateaued at similar concentrations [118, 
119]. Researchers have attributed acquired resistance to PTX to the activation of the NF-κB protein, 
which controls DNA transcription, and the induction of the Pregnane X receptor, which senses 
foreign substances in the body [119].  
Furthermore, the IC50 value for this cell line was 1.69 nM. This IC50 value is lower than 
those found in literature. For instance, in one study, researchers observed the effects of PTX (0 to 
300 nM) on MDA-MB-231 breast cancer cells [120]. The IC50 value for this study was 8 nM [120]. 
Several factors could have contributed to the discrepancy in IC50 values such as different drug 
resistance rates and PTX concentration ranges. Therefore, it is recommended that researchers 
conduct this study several times on the same cell culture to confirm results for literature comparison.  
In addition to cell viability, the cells were imaged to visually observe the cells after being 
treated with PTX. Control cells, cells not exposed to PTX, were used as the baseline for 100% cell 
viability (Figure 5.2). 
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Figure 5.2: Control cells not exposed to paclitaxel in resazurin assay. These cells were used as a baseline to compare 
viability of cells exposed to PTX. 
A majority of the cells were characterized by the typical shape of a breast cancer cell, a large nuclear 
mass with two tendrils opposite each other (Figure 5.2). This shape gave the cells a stretched, 
elongated appearance. The cells treated with a range of PTX concentrations were compared to 
control cells (Figure 5.3). 
 
Figure 5.3: Cells exposed to varying concentrations of paclitaxel under 10x magnification. Concentrations: Top row, 
left to right: 0.00564 nM, 0.0169 nM, 0.0508 nM, 0.152 nM. Middle row, left to right: 0.45 nM, 1.37 nM, 4.11 nM, 
12.34 nM. Bottom row, left to right: 37.03 nM, 111.11 nM, 333.33 nM, 1000 nM. 
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The cells exposed to the lowest concentrations of PTX had a similar appearance to the control cells 
(Figure 5.3). As the PTX concentration increased, the amount of metabolically active cells 
consistently decreased, and the appearance of these cells also changed. This change was first 
noticeable when cells were exposed to 0.45 nM PTX (Figure 5.3). Additionally, the number of cells 
in the images visibly decreased consistently until the concentration of 37 nM, where the images of 
increasing concentrations seem quite similar (Figure 5.3). Furthermore, the cells at the highest 
concentrations of PTX did not have the same tendrils associated with healthy cells, rather they were 
more oval-shaped (Figure 5.3). These images are supplemental to the resazurin assay results, and 
confirm the effectiveness of PTX treatment on breast cancer cells.  
5.4 Conclusions 
A breast cancer cell cytotoxicity model was developed with a range of PTX concentrations 
to kill MDA-MB-231 in vitro. The optimal PTX concentration for treatment was found to be 37 nM. 
This concentration results in the lowest viability of the cells (25%). As mentioned in Chapter 4.3.3, 
the plant cell culture (PCC) delivery system released PTX at concentrations of 8.5x10-4 mg/mL, or 
995 nM. This concentration is above the minimum suggested PTX concentration, meaning the 
delivery system would be efficient in treating breast cancer cells. Additionally, the lowest PTX 
concentration for treatment was determined to be 0.45 nM, the concentration at which the percent 
viability of cells began to decrease. However, it is advisable to use higher concentrations, of at least 
37 nM, which results in the lowest cell viability, to prevent surviving cells from developing PTX 
resistance due to non-lethal exposure.  
These experiments suggest that the developed drug delivery system for PTX through PCC 
will release sufficient PTX concentrations to kill MDA-MB-231 breast cancer cells Follow up 
research should be performed to further understand the cytotoxic properties of PTX produced by 
PCC and released from alginate hydrogel microbeads. These tests should entail a comparison of pure 
PTX to PTX produced in PCC to confirm the hypothesized synergistic effects PTX has with other 
naturally produced metabolites, such as flavonoids and phenolics. Synergistic interactions between 
PTX and other specialized metabolites may cause PTX’s cytotoxic properties to be enhanced; thus 
resulting in greater cell death at lower PTX concentrations. Additionally, to confirm that the drug 
delivery vehicle is not cytotoxic, cells should be introduced to calcium alginate. These experiments 
were going to be performed in D term; however, due to COVID-19 restrictions on lab access, 
additional experimentation was not possible. 
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Chapter 6: Pharmacokinetics of Paclitaxel Release System 
 
Pharmacokinetics refer to the pathways a drug undergoes in the body and is described 
through the drug’s administration/absorption, distribution, metabolism, and excretion (ADME) 
properties (Figure 6.1) [121].  
 
 
Figure 6.1. Overview of pharmacokinetics [122]. Image citation: Häggström, Mikael (2014). "Medical gallery of Mikael 
Häggström 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 2002-4436. Public Domain. 
 
For local administration of chemotherapy drugs, the compounds are applied directly to the tumor 
site through topical dosage forms. For instance, patients with basal cell carcinoma, a type of skin 
cancer, apply imiquimod cream (Aldara®) directly onto the skin [123]. Similarly, drug delivery 
vehicles can be implanted directly onto tumor sites inside of the body to target the release of 
anticancer drugs, such as the use of carmustine-loaded wafers to treat patients with brain tumors 
[14]. Once administered, cancerous tissues and cells absorb the drug for tumor cytotoxicity. Any 
drug compounds not absorbed into the tumor can diffuse into the circulatory system to be distributed 
to metabolism sites. Within the circulatory system, the drugs bind to plasma proteins [124]. For 
instance, weak acids and neutral drugs bind to albumin, whereas basic drugs bind to glycoproteins 
and red cell surface proteins [124]. The circulatory system distributes the drug compounds to either 
the liver or kidneys for metabolism [124]. The liver detoxifies and facilitates excretion of lipid-
soluble drugs by enzymatically converting the lipid-soluble compounds to water-soluble compounds 
[124]. The most common form of conversion is Phase I metabolism, in which the drug is converted 
to a more polar compound by introducing polar functional groups [124]. Cytochromes P450 
(CYP450s), hemoproteins that break down drug molecules into metabolic conjugates with reduced 
bioefficacy, catalyze this type of metabolism [124, 125]. If the body does not eliminate the metabolic 
conjugates rapidly, the drug may be further metabolized by Phase II metabolism, in which the newly 
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established polar group conjugates with endogenous compounds such as glucuronic acid, sulfuric 
acid, or amino acids [124]. Once converted into water-soluble compounds, the body may excrete the 
metabolized drug through feces, or it may undergo further metabolism in the kidneys [124]. Kidneys 
metabolize water-soluble drugs by filtering out compounds with less than 60,000 Da from blood and 
transporting the compounds into urine for excretion [126]. 
Ultimately, pharmacokinetic analyses allow researchers and practitioners to understand 
appropriate drug administration for patients. This chapter details the ADME properties of each 
component for the optimized release system consisting of paclitaxel (PTX), flavonoids, phenolics, 
alginate, and plant cell culture (PCC) material.  
 
6.1 ADME of Release System Components 
 
 The hypothesized pharmacokinetics map for the optimized PTX release system is shown in 
Figure 6.2. 
 
 
Figure 6.2. Pharmacokinetics of the paclitaxel release system [106, 127-129].  
 
The specific ADME for each component of the system including PTX, flavonoids, phenolics, 
alginate, and PCC material are further detailed in the subsequent sections of this chapter.  
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6.1.1 Administration 
 For this system, 2.8 mm-diameter alginate microbeads loaded with Taxus PCC are surgically 
implanted onto a tumor site for a 24-hr targeted drug release to treat breast cancer patients. The 
alginate microbeads have a loading capacity of 77 mg PCC material/ mL alginate; therefore, the 
bead size is subject to change depending on PTX concentrations retained in the material through 
processing. For this implantation, the PCC under analysis contains 4.1 x 10-5 mg/mL PTX, 0.22 
mg/mL flavonoids, and 0.15 mg/mL phenolics (as described in Chapter 3). Approximately 10.4 mg 
of lyophilized PCC is loaded into each alginate hydrogel microbead (methods detailed in Chapter 
4), with each bead having respective PTX, flavonoid, and phenolic concentrations of 0.025 mg/mL, 
135 mg/mL, and 92 mg/mL. In a nine bead system (4.68 mm3 total volume), there is approximately 
93.6 mg of plant cell material, and 90 µL of alginate. These loading amounts and concentrations are 
subject to alteration dependent on a patient’s height, weight, age, and tumor characteristics.  
6.1.2 Distribution 
Paclitaxel 
Over 24 hr, approximately 32.5% of the PTX (Chapter 4.3.3) is released from the microbeads 
to deliver a PTX concentration of 8.5 x 10-4 mg/mL to the tumor. PTX binds to tubulin in the tumor 
which activates apoptosis via phosphorylation pathways and subsequent cytotoxicity, thus, killing 
75% of the tumor cells [127]. The remaining PTX that is released into the body travels via the 
circulatory system to its metabolism site.  
The remaining PTX absorbs into the breast tissues and diffuses into the circulatory system 
through either the internal mammary vein or intercostal veins. Here, PTX may potentially bind to 
hydrophobic sites along the venous tissues and it can take up to 4 hr for the drug to diffuse through 
the venous wall [130]. Once the drug has entered the circulatory system, the compound binds to 
various plasma proteins including serum albumin, glycoproteins, and platelets [131]. PTX travels 
through the veins to the liver to be metabolized [127].  
Flavonoids and Phenolics 
Over 24 hr, approximately 32.5% of the flavonoids and phenolics are released from the 
microbeads to deliver a flavonoid concentration of 43.9 mg/mL and a phenolic concentration of 29.9 
mg/mL to the tumor site. These metabolites may inhibit cell proliferation, induce apoptosis and cell 
arrest, or decrease the expression of pro-survival factors within the tumor cells; thus, enhancing the 
cytotoxic properties of PTX [48-50]. The remaining metabolite concentrations that are released into 
the body travel via the circulatory system metabolic sites.  
The remaining metabolites absorb into the breast tissues and diffuse into the circulatory 
system through either the internal mammary vein or intercostal veins. Due to the hydrophilic 
properties of these metabolites, the compounds are able to directly enter the bloodstream via passive 
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diffusion. The compounds bind to glycoproteins in the plasma and travel through the circulatory 
system to the liver for metabolism [129, 132].  
Alginate 
Over 24 hr, a majority of the alginate degrades from natural calcium chelators, such as 
parathyroid hormones, that exist at the site of the tumor [106]. The degraded alginate either remains 
at the tumor site, or is carried away by blood. Studies suggest that up to 70% of the implanted alginate 
remains at the tumor site [133]. Additionally, in vivo studies show that there are no adverse side 
effects when 13,500 mg sodium alginate/kg body weight (BW) are administered per day, and no 
associated genotoxicity or carcinogenic effects when 37,500 mg sodium alginate/kg BW are 
administered per day [134]. These amounts of alginate are well beyond the amount of alginate that 
is used in the PTX DDS. For the alginate that is absorbed into the bloodstream, it is distributed 
through the body by the circulatory system to the kidney for metabolism [106].  
Plant Cell Culture Material 
The plant cell material primarily consists of cellulose; therefore, a majority of the 
encapsulated material remains at the tumor site because the human body does not have the necessary 
cellulase enzymes to break down the cellulose [135]. Considering plant cell material has not been 
used for drug delivery previously, it is unclear as to what adverse reactions that may result from the 
remaining biomass. However, it is hypothesized that some of the plant cell matrix may be broken 
down by macrophage phagocytosis, which can allow some of the particulates to be absorbed into 
the circulatory system for further metabolism [135].  
6.1.3 Metabolism 
Paclitaxel 
 In the liver, PTX is hydroxylated by hepatic CYPs (CYP2C8 and CYP3A4) to produce 
metabolites 6-α-hydroxy-paclitaxel and 3’-p-hydroxyphenyl-paclitaxel, which are upwards of thirty 
times less cytotoxic than PTX [127, 136]. These metabolite conjugates undergo biliary excretion to 
be eliminated from the body [136].  
Flavonoids and Phenolics 
Despite the natural benefactors of flavonoids and phenolics, the body continues to recognize 
these compounds as xenobiotics, or foreign substances, that must undergo Phase II metabolism in 
the liver to diminish each compound’s bioefficacies [129]. These metabolite conjugates undergo 
biliary excretion to be eliminated from the body [129].  
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Alginate 
The human body does not have the necessary enzyme, alginate lyase, to adequately 
breakdown and metabolize alginate. However, research has suggested that the degradation of 
alginate blocks can be aided by partial oxidation of the chains prior to implantation [106]. Alginate 
blocks that are not sufficiently degraded enter the bloodstream and are sent to the kidneys, where it 
undergoes glomerular filtration.  
Plant Cell Culture Material 
 Macrophage phagocytosis can contribute to the breakdown of cellulose, which is a primary 
component of the plant cell matrix. However, further metabolism and breakdown of the plant cell 
culture material is unlikely due to its rigidity [135]. There is a need for more research in this area, 
as implantation and metabolism of plant cell material has not been extensively studied. 
6.1.4 Excretion  
Within 24 hr, a majority of the PTX, flavonoids, phenolics, and alginate is eliminated from 
the body through urine and feces [106, 127, 129]. However, there are several concerns that must be 
addressed with regards to the excretion of this system’s components. Ten percent of the PTX is 
eliminated via renal excretion; therefore, it is recommended that patients with renal failure be 
administered lower doses of the drug [129]. With alginate, due to higher molecular weight blocks, 
the polymer may not get completely removed from the body, as it would be bigger than the renal 
clearance threshold of the kidneys [106]. Alginate blocks that have a molecular weight less than 
60,000 Da are small enough to pass through the kidneys and get excreted in urine, while the larger 
polymer blocks continue to circulate in the body, not readily accumulating in any tissue [106]. For 
the remaining plant cell matrix, most of the material will remain at the site of the tumor after 24 hr, 
while some of the smaller molecules will pass through the kidneys to be excreted in urine.  
6.2 Conclusions 
 
 Following the implantation of PTX-loaded alginate microbeads, absorption, distribution, 
metabolism, and excretion processes occur for the PTX, flavonoids, phenolics, alginate, and plant 
cell material of the delivery system. The manner of these pharmacokinetic processes depends on the 
material. While all of the materials are administered through the same method, the PTX, flavonoid, 
and phenolic compounds are metabolized and can be broken down by the body. Conversely, the 
remnants of the alginate microbeads and the additional plant cell material are unable to be 
metabolized and fully degraded due to a lack of necessary enzyme systems. Although the alginate 
and plant cell matrix cannot be degraded, these materials are still excreted with the plant metabolites, 
given that they are small enough to clear the renal clearance threshold of the kidneys. Molecules that 
are bigger than this threshold will continue to circulate in blood throughout the body, eventually 
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accumulating in tissues. However, it is expected that these materials will not cause further harm to 
the body. 
There is a lack of research on the pharmacokinetics of materials in PCC drug delivery 
systems, as this is a novel delivery device. With the primary aspects of the pharmacokinetics for this 
system considered, a PCC drug delivery system is promising for future local drug delivery, as there 
does not appear to be an increase in risk or danger involved with such a treatment. A big concern 
regarding the pharmacokinetics of this system is the relatively unknown distribution, metabolism, 
and excretion of the plant cell material. This area would have to be researched and adequately tested 
before success of this system could be considered.  
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Chapter 7: Discussion and Future Research 
 
This Major Qualifying Project (MQP) investigated the potential for local administration of 
paclitaxel (PTX) via targeted delivery of processed Taxus plant cell cultures (PCC). The studies 
analyzed sought to provide insight on the delivery of PTX through PCC by the following aims: 
 
Aim 1: Develop a wash process that retains PTX, flavonoid, and phenolic compounds, and prepare 
PCC material for encapsulation. 
Aim 2: Optimize delivery of PTX, flavonoid, and phenolic compounds by encapsulating PCC 
material in a biomaterial suitable for desired delivery. 
Aim 3: Establish an in vitro model to optimize drug delivery design for maximum breast cancer cell 
culture cytotoxicity and predict release studies for PCC delivery.   
Aim 4: Understand pharmacokinetics for components of the optimized drug delivery system to 
determine feasibility and administration parameters. 
 
This chapter summarizes the key results of these aims as well as provides suggestions for 
future research opportunities to further understand targeted delivery of PTX through PCC.  
 
7.1 Retention of Paclitaxel, Flavonoids, and Phenolics Through Wash Processing 
 
While the washing process detailed in Chapter 3 can retain a significant amount of PTX, 
flavonoids, and phenolics through processing, there are several variables that can interfere with 
optimization of the process. For instance, the density of the initial PCC being washed impacted 
metabolite retention. If the initial sample density was relatively low, the pellet containing the cells 
after centrifugation was not sufficiently packed. This resulted in losing cells, and the cell-associated 
metabolites, in the removal of the supernatant. To maximize metabolite retention, cells should be 
transferred properly every 2 weeks (as detailed in Chapter 3.2.1), ensuring that there is a higher 
density of cells in the media. If a significant amount of cells are lost in transferring, it is 
recommended to allow the cells to grow for an extra day or two before elicitation to increase the 
density of cells before processing.  
Additionally, researchers should perform further experiments using different solvents other 
than deionized water to wash the PCC. Due to the hydrophobic properties of PTX, polar protic 
solvents, such as alcohols or ammonia, can prevent significant losses of PTX because the drug 
compound cannot dissolve into these solvents [94]. Different solvents may also increase the retention 
of other metabolites in the PCC such as flavonoids and phenolics, the latter of which showed a 
statistical loss in our experiments. Researchers can test these different solvents individually, or as 
mixtures to optimize the retention of each metabolite of interest. However, while retention of PTX, 
flavonoids, and phenolics is important, the optimal solvent is one that retains the greatest 
concentration of PTX. By retaining greater amounts of PTX, less PCC material is needed for 
encapsulation to achieve cytotoxicity. 
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7.2 Optimization of Delivery 
 
To optimize the local delivery of PTX through PCC, experiments were performed to 
determine the release of Nile Red (NR) and PTX from alginate hydrogel microbeads; however, 
future research is needed to further optimize the delivery vehicle and model system, and understand 
the release of PTX from encapsulated PCC.  
The degradation profile of PTX at 37°C should first be understood to determine an 
appropriate material to minimize any potential degradation of PTX. Experiments aimed at 
determining the release of PTX from alginate hydrogels showed variability in the measured PTX 
concentrations. This variability may be due to PTX degrading through the incubation process, and a 
different temperature may have to be used for incubation. Due to this uncertainty, it is necessary to 
perform testing in order to understand the degradation of PTX at 37°C, and if this is determined to 
be an issue, a new temperature must be determined for the incubation process. 
To optimize the delivery vehicle, other natural and synthetic polymers should be explored, 
and compared to the release kinetics collected from the alginate hydrogel studies. Utilizing materials 
such as gelatin, silk, dextran, collagen, and albumin, which have been successfully utilized as 
biomaterial options for drug delivery systems (DDSs), may improve the stability of the hydrogels 
[14]. Several of these polymers can also be used together to increase the stability of the polymers to 
sustain constant drug release rates, such as the addition of chitosan to alginate [137]. Additionally, 
synthetic polymers should be explored as a PCC DDS. At the onset of this project, polyvinyl alcohol 
hydrogel was utilized, but it proved to be too unstable for a sustained drug delivery. However, further 
research and testing should be carried out with synthetic polymers to properly explore their PCC 
drug delivery potential [138].  
In addition to exploring different materials, altering the form factors of polymers may 
enhance their drug delivery kinetics. While hydrogel microbeads are a common and widely tested 
form factor for drug-loaded implants, others such as nanoparticles, polymeric films, rods, and wafers 
have been tested and have demonstrated promising results for delivery of PTX [14, 97]. Different 
form factors should be explored to achieve different release profiles of the drug. To shift the release 
profile of a drug to be faster, smaller form factors, such as nanoparticles, should be investigated, as 
a greater total surface area of the material will increase the early rate of drug release [14]. 
Conversely, larger geometries, like wafers, will have a longer duration, more delayed drug release 
[14]. For the use of a PCC DDS to treat breast cancer, nanoparticle formulations should be an 
immediate area for future research given their noted success in other studies involving PTX and 
breast cancer treatment [14, 139]. 
Because PTX is an expensive compound to be consistently used in release studies, further 
research on using NR as a model for PTX should be carried out to minimize PTX usage. A NR 
model was utilized due to its similar solubility and size to PTX. Additionally, the compound is 
pigmented, which allows for the use of a UV-Vis spectrometer to obtain release concentrations. A 
UV-Vis spectrometer is a simpler analyzing method when compared to UPLC, which can be time 
extensive. However, results from the release studies outlined in Chapter 4 demonstrate differences 
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in release profiles for the two compounds. More research should be conducted on using NR as a 
model for PTX, as well as research on other pigmented materials that could accurately simulate the 
release of PTX in a PCC DDS.  
Lastly, future experimentation to determine the release of PTX through PCC from alginate 
hydrogel microbeads should be conducted. From initial experiments, it was determined that 
approximately 77 mg of PCC was the PCC volume threshold that could be encapsulated in 1 mL of 
alginate whilst maintaining uniform hydrogel microbeads. For future research, release of PCC from 
alginate hydrogels should be tested to confirm that a successful and concentrated drug delivery with 
PCC is possible.  
 
7.3 Testing Optimized Drug Delivery System on Mammalian Cell Culture 
 
 Due to limitations from the COVID-19 pandemic and lack of access to the lab, not all the 
planned mammalian cell culture experiments were able to be conducted. While the effects of pure 
PTX on MDA-MB-231 breast cancer cells were determined, the optimized DDS was not able to be 
tested. This experiment would entail seeding a 96-well plate with 5,000 cells per well of MDA-MB-
231 cells. In addition to a set of cells untreated as a control, these cells would be treated with 2 µL 
of either of the following solutions: release media from PCC encapsulated in alginate, alginate, or 
pure PTX. These cells would be treated with 2 µL to better replicate our testing we have performed. 
Treating cells with the release media would ensure that the DDS is able to release a high enough 
PTX concentration to kill the cells. Treating cells with alginate would ensure that the delivery vehicle 
is not cytotoxic to the cancer cells. Lastly, treating cells with pure PTX would serve as a comparison 
to the PTX released from the PCC. It is hypothesized that other naturally produced metabolites 
enhance the cytotoxic properties of PTX. The cells would be treated for periods of 12 and 24 hr to 
analyze the effects of drug exposure time on cell viability. Although 12 and 24 hour tests were 
performed in this MQP, it may be advisable to perform 48 hr tests, as previous studies show the 
doubling time of MDA-MB-231 cells to be about 30 hr and up to 40 hr [140]. Because PTX targets 
the microtubules of a cell, it is important to allow sufficient time for as many of the cells to double 
as possible. Cell viability data would be collected with the same methods detailed in Chapter 5.2. It 
is hypothesized that the designed DDS will successfully kill the cells considering the desired release 
concentration falls within the efficient range of treatment concentrations determined by the study 
detailed in Chapter 5. Effective PTX concentrations for breast cancer cell treatment ranges from 37 
to 1000 nM, as this is the highest concentration tested. Higher concentrations may be usable, but 
testing may be necessary to determine how these higher concentrations will act, and if they introduce 
any new side effects as opposed to relatively low concentrations. However, the delivery system 
under analysis is expected to release 995 nM of PTX, which we calculated in section 4.3.3, which is 
within our tested and effective range. 
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7.4 Pharmacokinetics of the Paclitaxel Release System 
 
This project hypothesized the pharmacokinetics of the proposed PTX release system based 
on literature review of current PTX treatment pharmacokinetics. The initial mapping of the system 
identified the administration, distribution, metabolism, and excretion (ADME) for each of the 
system’s components—PTX, flavonoids, phenolics, alginate, and PCC material. Due to the lack of 
research regarding delivering drugs produced by PCC, researchers must conduct further 
experimental studies to fully understand the ADME for this release system; which, in turn, would 
allow practitioners to develop appropriate treatment plans for their patients with this system.  
Prior to clinical studies, researchers should conduct experiments on mammalian disease 
models, such as mice bearing subcutaneous or orthotopic xenograft breast cancer tumors, to analyze 
the ADME of this system [141]. To analyze the administration and absorption of the system’s 
compounds, researchers would have to implant the optimized drug delivery system onto the tumor 
site. At this time, researchers should collect data regarding changes in tissue concentrations for each 
of the system’s components [142]. However, to evaluate this data for flavonoids and phenolics, 
researchers would need to identify particular metabolites of interest prior to testing. By collecting 
tissue samples at regular time intervals, researchers can construct concentration-versus-time plots to 
identify the release profile of each component. From these plots, researchers can extrapolate 
bioavailability, the rate at which each component accesses the tumor site, for each of the components 
by calculating the area under the curve (AUC) [143]. Similarly, distribution experiments should 
entail measuring drug concentrations in plasma. From these experiments, researchers should collect 
blood samples at regular time intervals and evaluate for absorption ratio and rate. Extrapolated from 
concentration-versus-time plots, absorption ratio (maximum concentration/AUC) can identify each 
component’s absorption rate constant [144]. By identifying these constants, researchers can 
determine how long each component takes to penetrate into the circulatory system from its 
administration. Furthermore, to understand the metabolism and excretion of each of the system’s 
components, researchers should assess concentrations of the components, as well as the suspected 
conjugate metabolites, in plasma, urine, bile, and feces. Throughout this process, researchers should 
collect samples at standard times and analyze the sample concentrations. Extrapolated information 
from model independent analytical models, such as minimum and maximum concentrations with 
associated times, mean residence time, half-life, and volume of distribution, can provide researchers 
with further insight into the system’s ADME [142]. By identifying the system’s minimum and 
maximum concentrations for PTX, researchers can determine if the system is releasing a drug 
concentration efficient for tumor cell cytotoxicity that does not cause further side effects to the 
patient. Additionally, mean residence time, the average time the component spends in the body, and 
half-life, the time for each component’s administered concentration to decrease by 50%, allows 
researchers to understand the amount of time between administration and excretion for each 
component [145]. Lastly, volume of distribution is the theoretical volume of the administered drug 
needed to achieve the desired release concentration and is used to adjust loading concentrations into 
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the delivery vehicle [146]. Overall, these experimental studies would help researchers gain a better 
understanding of administering PTX through PCC and other plant-based drugs locally.  
 
7.5 Reflections 
 
 A previous MQP group began the investigation for local administration of PTX via delivery 
of processed Taxus PCC by increasing cell-associated metabolite accumulation through processing 
procedures, removing DNA from the cells for biocompatibility, and comparing the release kinetics 
of free PTX to PTX encapsulated in alginate hydrogel microbeads [16]. Moving forward, this MQP 
sought to improve the processing procedure to increase cell-associated metabolite accumulation. 
Formerly, the PCC was washed from the plant media after lyophilization. By washing after 
lyophilization, along with using a Buchner funnel to dry the washed cell material, 85% of 
metabolites, such as PTX, were lost through processing [16]. However, by altering the processing 
procedure to lyophilize the cells after washing, 75% flavonoids, 40% phenolics, and 68.3% PTX 
were retained. Furthermore, this MQP sought to extend the knowledge of PTX release kinetics 
through various polymeric biomaterials. Previously, alginate, a natural polymer, was used to 
encapsulate PTX. The alginate hydrogel microbeads used in this study were unable to maintain 
integrity over 12 hr [16]. However, this MQP improved the durability of the alginate microbeads by 
altering the viscosity of the alginate so that the beads could withstand a 24 hr delivery period; thus, 
increasing the control over the system’s release. Moreover, this MQP expanded the investigation for 
local administration of PTX by understanding the cytotoxic effects on in vitro breast cancer cell 
models, and the pharmacokinetics of the optimized delivery system. Overall, previous studies in 
conjunction with the extension in knowledge gained through this MQP expand the understanding of 
drug delivery using plant cell culture, and thus advances oncology treatments. 
 
.  
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Appendix A. Raw Data 
 
A.1 Chapter 3 Data 
 
A.1.1 Phase 1 
 
Table A1: UPLC standard curve data 
 
Standard Curve: Area = 35162*Concentration R2: 0.9991 y-intercept: 0 
Standard 
Run Number 
Standard Concentration 
(mg/L) 
Retention Time (min) Area (μV*sec) 
1 0 0 0 
1 3.125 2.712 95649 
1 6.25 2.712 211418 
1 12.5 2.712 421461 
1 25 2.716 851965 
1 50 2.729 1776391 
2 0 0 0 
2 3.125 2.720 95421 
2 6.25 2.722 211405 
2 12.5 2.716 421105 
2 25 2.715 849731 
2 50 2.713 1781005 
  
 
Table A2: Paclitaxel retention through processing for various initial culture samples 
 
Sample Retention Time (min) Area (μV*sec) Sample 
Concentration 
PTX (mg/L) 
Initial Culture 
(IC) 1 
2.714 261168 7.427564 
IC2 2.708 225267 6.406547 
IC3 2.708 225118 6.402309 
1.1  2.707 29638 0.842899 
76 
(Tube No. Wash 
No.) 
2.1 2.709 24992 0.710767 
3.1 2.710 25515 0.725641 
4.1 2.712 12025 0.341989 
5.1 2.716 11934 0.339400 
6.1 2.715 12787 0.363660 
1.2 2.714 36007 1.024032 
2.2 2.713 16724 0.475627 
3.2 2.713 25227 0.717451 
4.2 2.716 5262 0.149650 
5.2 2.717 8156 0.231955 
6.2 2.718 8307 0.236249 
1.3 2.719 21371 0.607787 
2.3 2.721 19279 0.548291 
3.3 2.721 12959 0.368551 
4.3 2.723 4872 0.138559 
5.3 2.724 4903 0.139440 
6.3 2.722 6718 0.191059 
Final Culture 
(FC) 1 
2.722 139095 3.955833 
FC2 2.721 160758 4.571924 
FC3 2.718 186166 5.294522 
FC4 2.716 122298 3.478130 
FC5 2.711 89890 2.556453 
FC6 2.712 130705 3.717223 
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A.1.2 Experiment 2 
 
Flavonoid Assay Data 
 
Table A3: Flavonoid assay standard curve data 
 
Standard Curve: Absorbance = 2.4043*Concentration R2: 0.9975 
y-intercept: 0 Blank Subtraction: 0.042 
Standard 
Concentration 
(mg/mL) 
0.000 0.100 0.200 0.400 0.600 0.800 1.000 
Absorbance 0.000 0.184 0.542 1.070 1.569 2.083 2.441 
  
Table A4: Flavonoid retention through processing and lyophilization 
Sample Absorbance Sample Concentration 
(mg/mL) 
IC 1 0.196 0.326082 
IC2 0.144 0.239571 
IC3 0.176 0.292809 
1.1 0.013 0.005407 
2.1 0.021 0.008734 
3.1 0.022 0.009150 
4.1 0.013 0.005407 
5.1 0.013 0.005407 
6.1 0.013 0.005407 
1.2 0.008 0.003327 
2.2 0.016 0.006655 
3.2 0.018 0.007487 
4.2 0.024 0.009982 
5.2 0.025 0.010398 
6.2 0.020 0.008318 
1.3 0.033 0.013725 
2.3 0.034 0.014141 
3.3 0.033 0.137250 
4.3 0.030 0.012478 
78 
5.3 0.031 0.012894 
6.3 0.028 0.011646 
Cells 0.037 0.015389 
Cells 0.074 0.030778 
Media 0.437 0.727031 
Media 0.301 0.500769 
FC1 0.106 0.176351 
FC2 0.118 0.196315 
FC3 0.118 0.196315 
FC4 0.113 0.187997 
FC5 0.182 0.302791 
FC6 0.126 0.209624 
FC1L 0.123 0.204633 
FC2L 0.157 0.261199 
FC3L 0.107 0.178014 
FC4L 0.138 0.229589 
FC5L 0.148 0.246226 
FC6L 0.133 0.221270 
  
Phenolic Assay Data 
 
Table A5: Phenolic assay standard curve data 
 
Standard Curve: Absorbance = 9.6261*Concentration R2: 0.9960 
y-intercept: 0 Blank Subtraction: 0.039 
Standard 
Concentration 
(mg/mL) 
0.000 0.025 0.050 0.075 0.100 0.150 0.200 
Absorbance 0.000 0.277 0.494 0.662 0.977 1.454 1.530 
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Table A6: Phenolic retention through processing and lyophilization 
Sample Absorbance Sample Concentration 
(mg/mL) 
IC 1 0.856 0.355700 
IC2 0.644 0.267606 
IC3 0.907 0.376892 
1.1 0.146 0.015167 
2.1 0.130 0.013505 
3.1 0.053 0.005506 
4.1 0.081 0.008415 
5.1 0.122 0.012674 
6.1 0.062 0.006856 
1.2 0.042 0.004363 
2.2 0.066 0.006856 
3.2 0.062 0.006441 
4.2 0.071 0.007376 
5.2 0.047 0.004883 
6.2 0.062 0.006441 
1.3 0.044 0.004571 
2.3 0.043 0.004467 
3.3 0.051 0.005298 
4.3 0.041 0.004259 
5.3 0.033 0.003428 
6.3 0.033 0.003428 
Cells 1.549 0.643667 
Cells 1.082 0.449611 
Media 0.249 0.025867 
Media 0.319 0.033139 
FC1 0.344 0.0142945 
FC2 0.321 0.133387 
FC3 0.294 0.122168 
80 
FC4 0.243 0.100975 
FC5 0.262 0.108871 
FC6 0.158 0.065655 
FC1L 0.331 0.137543 
FC2L 0.376 0.156242 
FC3L 0.368 0.152918 
FC4L 0.299 0.124246 
FC5L 0.307 0.127570 
FC6L 0.421 0.174941 
  
UPLC Data 
 
Table A7: UPLC standard curve  
 
Standard Curve: Area = 25825*Concentration R2: 0.9977 y-intercept: 0 
Standard Run 
Number 
Standard Concentration 
(mg/L) 
Retention Time (min) Area (μV*sec) 
1 0 0 0 
1 3.125 2.912 51087 
1 6.25 2.914 141016 
1 12.5 2.915 287253 
1 25 2.915 639419 
1 50 2.913 1298257 
2 0 0 0 
2 3.125 2.989 51526 
2 6.25 2.999 141721 
2 12.5 3.016 287507 
2 25 3.008 643980 
2 50 3.000 1314609 
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Table A8: Paclitaxel retention through processing and lyophilization  
 
Sample Retention Time (min) Area (μV*sec) Sample Concentration 
(mg/L) 
IC1 2.912 10989 0.425517909 
IC2 2.903 10812 0.418664085 
IC3 2.904 13809 0.534714424 
Cells 3.005 7547 0.292236205 
Cells 3.009 10848 0.420058083 
Media 3.014 40 0.001548887 
Media 3.012 78 0.003020329 
FC1 3.005 1254 0.048557599 
FC2 3.005 1419 0.054956757 
FC3 3.004 1511 0.058509197 
FC4 3.004 1760 0.068151016 
FC5 3.000 1533 0.059361084 
FC6 3.000 1620 0.062729913 
FC1L 3.000 1375 0.053242982 
FC2L 3.001 782 0.030280736 
FC3L 2.997 1165 0.045111326 
FC4L 2.999 778 0.030125847 
FC5L 2.996 1145 0.044336883 
FC6L 2.992 1169 0.045266215 
 
A.2 Chapter 4 Data  
 
A.2.1 Nile Red Dye Encapsulated in Alginate Hydrogel Release Profile 
 
Nile Red Standard Curve Data 
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Table A9: Nile red standard curve at t = 0 hr data 
 
Standard Curve: Absorbance = 27.697*Concentration R2: 0.9976 
y-intercept: 0 Blank: 0.046  
Standard concentration 
(mg/mL) 
Absorbance (nm) 
1.25x10-2 0.339 
6.25x10-3 0.183 
3.125x10-3 0.091 
1.563x10-3 0.051 
7.81x10-4 0.023 
3.91x10-4 0.012 
1.95x10-4 0.008 
9.77x10-5 0.006 
4.88x10-5 0 
  
Table A10: Nile red standard curve at t = 2 hr data 
Standard Curve: Absorbance = 27.949*Concentration R2: 0.9918 
y-intercept: 0 Blank: 0.037 
Standard concentration 
(mg/mL) 
Absorbance (nm) 
1.25x10-2 0.340 
6.25x10-3 0.184 
3.125x10-3 0.095 
1.563x10-3 0.058 
7.81x10-4 0.029 
3.91x10-4 0.020 
1.95x10-4 0.018 
9.77x10-5 0.012 
4.88x10-5 0 
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Table A11: Nile red standard curve at t = 7 hr data 
Standard Curve: Absorbance = 27.131*Concentration R2: 0.9985 
y-intercept: 0 Blank: 0.045  
Standard concentration (mg/mL) Absorbance (nm) 
1.25x10-2 0.334 
6.25x10-3 0.177 
3.125x10-3 0.087 
1.563x10-3 0.048 
7.81x10-4 0.022 
3.91x10-4 0.012 
1.95x10-4 0.008 
9.77x10-5 0.007 
4.88x10-5 0 
 
Table A12: Nile red standard curve at t = 10 hr data 
Standard Curve: Absorbance = 26.899*Concentration R2: 0.9988 
y-intercept: 0 Blank: 0.045 
Standard concentration (mg/mL) Absorbance (nm) 
1.25x10-2 0.332 
6.25x10-3 0.174 
3.125x10-3 0.086 
1.563x10-3 0.047 
7.81x10-4 0.022 
3.91x10-4 0.012 
1.95x10-4 0.009 
9.77x10-5 0.007 
4.88x10-5 0 
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Table A13: Nile red standard curve at t = 23 hr data 
Standard Curve: Absorbance = 26.123*Concentration R2: 0.9986 
y-intercept: 0 Blank: 0.046 t= 23 hr 
Standard concentration (mg/mL) Absorbance (nm) 
1.25x10-2 0.322 
6.25x10-3 0.170 
3.125x10-3 0.083 
1.563x10-3 0.046 
7.81x10-4 0.021 
3.91x10-4 0.012 
1.95x10-4 0.009 
9.77x10-5 0.006 
4.88x10-5 0 
 
Nile Red Release Data 
 
Table A14: Three beads containing 3% low viscosity sodium alginate release data 
 
Time 
(hr) 
Sample 1 Sample 2 Sample 3 
  Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
0 0 0 0 0 0 0 
0.5 0.0003 0.00011 0.003 0.00011 0.004 0.00014 
1 0.013 0.00047 0.013 0.00047 0.014 0.00050 
1.5 0.015 0.00054 0.013 0.00047 0.017 0.00061 
2 0.011 0.00039 0.010 0.00036 0.024 0.00086 
3 0.019 0.00068 0.016 0.00057 0.016 0.00057 
4 0.026 0.00093 0.023 0.00082 0.028 0.00100 
5 0.019 0.00070 0.017 0.00063 0.014 0.00052 
6 0.036 0.00133 0.030 0.00111 0.028 0.00103 
7 0.044 0.00162 0.042 0.00155 0.031 0.00114 
8 0.049 0.00181 0.045 0.00166 0.044 0.00162 
85 
9 0.06 0.00223 0.048 0.00178 0.052 0.00193 
10 0.068 0.00253 0.075 0.00279 0.081 0.00301 
11 0.066 0.00245 0.068 0.00253 0.073 0.00271 
12 0.067 0.00249 0.072 0.00268 0.070 0.00260 
23 0.072 0.00276 0.07 0.00268 0.067 0.00256 
  
Table A15: Nine beads containing 3% low viscosity sodium alginate release data 
 
Time 
(hr) 
Sample 1 Sample 2 Sample 3 
  Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration
NR (mg/mL) 
0 0 0 0 0 0 0 
0.5 0.004 0.00014 0.004 0.00014 0.004 0.00014 
1 0.014 0.00050 0.013 0.00047 0.013 0.00047 
1.5 0.031 0.00111 0.014 0.00050 0.019 0.00068 
2 0.024 0.00086 0.015 0.00054 0.018 0.00064 
3 0.019 0.00068 0.030 0.00107 0.039 0.00140 
4 0.042 0.00150 0.033 0.00118 0.044 0.00157 
5 0.038 0.00140 0.036 0.00133 0.045 0.00166 
6 0.044 0.00162 0.052 0.00192 0.061 0.00225 
7 0.054 0.00199 0.059 0.00218 0.068 0.00251 
8 0.069 0.00254 0.063 0.00232 0.078 0.00288 
9 0.088 0.00327 0.067 0.00249 0.082 0.00305 
10 0.134 0.00498 0.091 0.00338 0.093 0.00346 
11 0.080 0.00297 0.086 0.00320 0.107 0.00398 
12 0..085 0.00316 0.094 0.00350 0.114 0.00424 
23 0.130 0.00498 0.112 0.00429 0.130 0.00498 
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Table A16: Three beads containing 5% low viscosity sodium alginate release data 
Time 
(hr) 
Sample 1 Sample 2 Sample 3 
  Absorbance 
(nm) 
Sample 
Concentration
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
0 0 0 0 0 0 0 
0.5 0.005 0.00018 0.004 0.00014 0.002 0.00007 
1 0.015 0.00054 0.013 0.00047 0.014 0.00050 
1.5 0.014 0.00050 0.014 0.00050 0.013 0.00047 
2 0.022 0.00079 0.018 0.00064 0.019 0.00068 
3 0.034 0.00122 0.024 0.00086 0.024 0.00086 
4 0.036 0.00129 0.033 0.00118 0.029 0.00104 
5 0.040 0.00147 0.030 0.00111 0.028 0.00103 
6 0.048 0.00177 0.042 0.00155 0.035 0.00129 
7 0.057 0.00210 0.043 0.00159 0.050 0.00184 
8 0.069 0.00254 0.057 0.00210 0.077 0.00284 
9 0.071 0.00264 0.064 0.00238 0.075 0.00279 
10 0.085 0.00316 0.073 0.00271 0.069 0.00257 
11 0.097 0.00361 0.088 0.00327 0.081 0.00301 
12 0.092 0.00342 0.093 0.00346 0.078 0.00290 
23 0.092 0.00352 0.090 0.00345 0.092 0.00352 
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Table A17: Nine beads containing 5% low viscosity sodium alginate release data 
 
Time 
(hr) 
Sample 1 Sample 2 Sample 3 
  Absorbance 
(nm) 
Sample 
Concentration
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
Absorbance 
(nm) 
Sample 
Concentration 
NR (mg/mL) 
0 0 0 0 0 0 0 
0.5 0.007 0.00025 0.002 0.00008 0.013 0.00049 
1 0.023 0.00082 0.014 0.00050 0.029 0.00104 
1.5 0.29 0.00104 0.019 0.00068 0.035 0.00125 
2 0.037 0.00132 0.026 0.00093 0.043 0.00154 
3 0.049 0.00175 0.043 0.00154 0.064 0.00229 
4 0.057 0.00204 0.051 0.00182 0.071 0.00254 
5 0.054 0.00199 0.056 0.00206 0.063 0.00232 
6 0.063 0.00232 0.065 0.00240 0.078 0.00287 
7 0.082 0.00302 0.084 0.00310 0.086 0.00317 
8 0.093 0.00343 0.093 0.00343 0.102 0.00376 
9 0.101 0.00375 0.102 0.00379 0.108 0.00402 
10 0.103 0.00383 0.106 0.00394 0.126 0.00468 
11 0.115 0.00428 0.098 0.00364 0.111 0.00413 
12 0.110 0.00409 0.130 0.00483 0.129 0.00480 
23 0.196 0.00750 0.174 0.00666 0.163 0.00624 
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Chelation of Alginate Beads in EDTA Data 
 
Table A18: EDTA standard curve data 
Standard Curve: Absorbance = 25.397*Concentration R2: 0.99992 
y-intercept: 0 Blank: 0.042 
Standard concentration (mg/mL) Absorbance (nm) 
2.50x10-2 0.635 
1.25x10-2 0.315 
6.25x10-3 0.161 
3.125x10-3 0.083 
1.563x10-3 0.041 
7.81x10-4 0.021 
3.91x10-4 0.010 
1.95x10-4 0.007 
9.77x10-5 0.003 
4.88x10-5 0 
 
Table A19: Chelation of 3% sodium alginate beads release data 
  3 Beads, 
Sample 1 
3 Beads, 
Sample 2 
3 Beads, 
Sample 3 
9 Beads, 
Sample 1 
9 Beads, 
Sample 2 
9 Beads, 
Sample 3 
Absorbance (nm) 0.014 0.013 0.013 0.014 0.009 0.014 
Sample 
Concentration 
NR (mg/mL) 
0.00055 0.00051 0.00051 0.00055 0.00035 0.00035 
 
Table A20: Chelation of 5% sodium alginate beads release data 
  3 Beads, 
Sample 1 
3 Beads, 
Sample 2 
3 Beads, 
Sample 3 
9 Beads, 
Sample 1 
9 Beads, 
Sample 2 
9 Beads, 
Sample 3 
Absorbance (nm) 0.005 0.008 0.002 0.046 0.041 0.034 
Sample 
Concentration 
NR (mg/mL) 
0.00020 0.00032 0.00008 0.00181 0.00161 0.00134 
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A.2.2 Paclitaxel Encapsulated in Alginate Hydrogel Release Profile 
 
Table A21: Mass release PTX from calcium alginate hydrogel microbeads after 12 hr 
Bead Concentration 
(mg/mL) 
Sample 1 
Concentration 
(mg/mL) 
Sample 2 
Concentration  
(mg/mL) 
Sample 3 
Concentration 
(mg/mL) 
0.1 0.000920 0.00473 0.00304 
0.05 0.00191 0.00184 0.00175 
0.01 0.000324 0.000636 0.000839 
0.005 0.000346 0.000243 0.000231 
0.001 0.0000127 0.00000828 0.0000523 
 
Table A22: Mass release PTX from calcium alginate hydrogel microbeads after 24 hr  
Bead Concentration 
(mg/mL) 
Sample 1 
Concentration 
(mg/mL) 
Sample 2 
Concentration  
(mg/mL) 
Sample 3 
Concentration 
(mg/mL) 
0.1 0.00196 0.00355 0.00336 
0.05 0.00182 0.000929 0.00128 
0.01 0.000468 0.000404 0.000776 
0.005 0.000286 0.000268 0.000314 
0.001 0.000141 0.0000834 0.000138 
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A.3 Chapter 5 Data 
 
A.3.1 Determining Optimal Paclitaxel Concentration for Breast Cancer Treatment 
 
Resazurin Assay  
 
Table A23: Raw resazurin assay data 
 
PTX Concentration (nM) Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
1000 139076 137661 140584 136555 N/A N/A 
333.33 143894 152717 148222 141078 N/A N/A 
111.11 152628 160830 151455 144338 N/A N/A 
37.03 163401 151153 166770 133789 N/A N/A 
12.34 254560 211292 219469 216599 N/A N/A 
4.11 26639 248287 262220 270820 N/A N/A 
1.37 357744 364835 333936 367403 N/A N/A 
0.45 455111 415126 455700 493272 N/A N/A 
0.152 559789 502711 514604 545391 N/A N/A 
0.0508 558300 525431 500233 522172 N/A N/A 
0.0169 553800 546179 530164 537358 N/A N/A 
0.00564 562725 540312 548663 509918 N/A N/A 
0 563545 601563 528135 542249 559981 545449 
Resazurin (Background) 1772 1413 1444 N/A N/A N/A 
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Table A24: Raw cell vitality data 
 
PTX Concentration 
(nM) 
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
1000 0.246673133 0.244135251 0.249377815 0.242151578 N/A N/A 
333.33 0.255314486 0.27113903 0.263076996 0.250263832 N/A N/A 
111.11 0.270979404 0.28569015 0.268875562 0.256110825 N/A N/A 
37.03 0.290301382 0.268333908 0.296343872 0.237190603 N/A N/A 
12.34 0.453800151 0.376196571 0.390862478 0.385714972 N/A N/A 
4.11 0.475464513 0.442549174 0.467538789 0.482963371 N/A N/A 
1.37 0.63886643 0.651584535 0.596165449 0.656190387 N/A N/A 
0.45 0.813499594 0.741784258 0.814555998 0.881943483 N/A N/A 
0.152 1.001245445 0.898872858 0.920203619 0.975421826 N/A N/A 
0.0508 0.99857484 0.939622449 0.894428426 0.93377725 N/A N/A 
0.0169 0.990503839 0.976835149 0.94811135 0.961014191 N/A N/A 
0.00564 1.006511326 0.966312356 0.981290342 0.911799016 N/A N/A 
0 1.007982041 1.076169452 0.944472225 0.969786474 1.001589808 0.975525853 
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Appendix B. Product Information 
  
B.1 Cell Lines 
 
Taxus cuspidata: 48.82A.11 
Breast cancer cell line: MDA-MB-231 
 
B.2 Chemicals and Reagents 
 
1-napthalenacetic acid: Sigma-Aldrich, St. Louis, MO 
Aluminum chloride: Sigma-Aldrich, St Louis, MO, 7784-13-6 
Ascorbic acid: Fisher Scientific, Hampton, NH 
Benzyl adenine: Sigma-Aldrich, St. Louis, MO 
BSA-PBS: sigma-Aldrich, St. Louis, MO 
Calcium chloride: C1016, Sigma-Aldrich, St. Louis, MO 
Catechin: Cayman Chemical, Ann Arbor, MI, 70940 
Citric Acid: PhytoTechnology Laboratories, Lenexa, KS 
Dimethylsulfoxide: Fisher Scientific, Fair Lawn, NJ 
DPBS (-): Cat # 21-031-CV, Corning 
EDTA disodium salt: Fisher Scientific, Fair Lawn, NJ 
Fetal bovine serum: Fisher Scientific, Hampton, NH  
Gallic acid: Acros Organics, Hampton, NH 
Gamborg-B5: PhytoTechnology Laboratories, Lenexa, KS 
L-glutamine: Caisson Laboratories, Smithfield, UT 
L-glutamine: Fisher Scientific, Hampton, NH 
Low viscosity sodium alginate: Alfa Aesar, Haverhill, MA 
Methyl jasmonate: Sigma-Aldrich, St Louis MO, 392707 
Nile red dye: Sigma-Aldrich, St. Louis, MO 
Paclitaxel: Alfa aesar, Ward Hill, MA 
Penicillin: Fisher Scientific, Hampton, NH 
Polyvinyl alcohol: 363170, Sigma-Aldrich, St. Louis, MO 
Sodium carbonate: Fisher Scientific, Hampton, NH, S263-500 
Sodium hydroxide: Sigma-Aldrich, St Louis, MO, 1310-73-2 
Sodium nitrite: Acros, NJ, 42435-5000 
Streptomycin: Fisher Scientific, Hampton, NH  
Sucrose: Caisson Laboratories, Smithfield, UT 
Trypsin: Cat # 25-053-Cl, Corning 
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B.3 Instruments and Products 
0.15 mL low-volume insert: VWR, Radnor, PA 
1.0 mL syringe: PrecisionGlide®, Becton Dickinson, Franklin Lakes, NJ 
22-gauge needle: PrecisionGlide, Becton Dickinson, Franklin Lakes, NJ 
2 mL UPLC vial: VWR, Radnor, PA 
50 mL conical tubes: Eppendorf, Hamburg, Germany 
-80 °C freezer: SU80XLE, Global Cooling Inc., Athens, OH 
Centrifuge: 5808F, Eppendorf, Hamburg, Germany 
Colorimetric absorbance reader: Accuskan GO, Fisher Scientific, Hampton, NH 
Evaporative centrifuge: Vacufuge plus, Eppendorf, Hamburg, Germany 
Fixed-angle rotor: FA-45-6-30, Eppendorf, Hamburg, Germany 
Fluorescence plate reader: Victor 3 – PerkinElmer 1420 Multilabel, Counter 
Gyratory shaker: New Brunswick Scientific Co. Inc, Edison, NJ, Model 44 
Inverted microscope: Nikon Eclipse TS100, Tokyo, Japan 
Microcentrifuge: 5242, Eppendorf, Hamburg, Germany 
MultiskanTM GO Microplate Spectrophotometer: Accuskan GO, Fisher Scientific, Hampton, NH 
Shaker: MaxQ 4000, Thermo Fisher Scientific, Waltham, MA 
Shaker: New Brunswick Scientific Co. Inc, Edison, NJ, Model 44 
Shelf lyophilizer: VirTis BenchTop Pro with Omnitronics, SP Scientific, Stone Ridge, NY 
Sonicator: Aquasonic 75HT, VWR, Radnor, PA 
UPLC: Waters, Milford, MA, Acquity UPLC H-Class 
Vortex: Scientific Mini Vortexer, VWR, Radnor, PA 
 
